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Abstract
Inflammatory Bowel Disease (IBD) affects over 1 million Americans and can
cause severe tissue damage and even death. TNF-α is a pro-inflammatory cytokine that is
found at elevated levels in IBD and plays a central role in inflammation in general.
Previous results in our laboratory showed that another pro-inflammatory cytokine, IL-1β,
induced chemokine secretion by intestinal epithelial cells (IEC) and that this induction
was mediated by the Rho-associated coiled-coil containing kinase (ROCK). Because
ROCK may be an important mediator of inflammation in IEC and because chemokines
play an important part in the progression of inflammation, we extended our investigations
to examine the role of ROCK in TNF-α-stimulated chemokine responses by IEC.
Inhibiting ROCK with the Y-27632 compound resulted in a significant, but incomplete,
suppression of TNF-α-induced CXCL8 mRNA expression and secretion in Caco-2 cells,
indicating that ROCK is required for the optimal CXCL8 production by IEC. ROCK
inhibition also blocked TNF-α-stimulated JNK phosphorylation in Caco-2 cells but did
not affect IκBα phosphorylation and degradation, suggesting a possible explanation for
the partial suppression of CXCL8 as CXCL8 is under the control of both NF-κB and the
JNK-activated AP-1 transcription factor. Unlike CXCL8, the production of two other
chemokines, CCL2 and CCL20, was enhanced by ROCK inhibition in Caco-2 cells
treated with either TNF-α or IL-1β, indicating that ROCK activity had a suppressive
effect on CCL2 and CCL20 responses. Further experiments showed that the ROCKdependent suppression was likely mediated by the ERK pathway since the MEK/ERK
iv

inhibitor, PD98059, had the same enhancement effect as the ROCK inhibitor on TNF-αinduced CCL2 secretion. However, the PI3K/Akt pathway was found not to contribute to
the effect. Additionally, inhibiting ROCK significantly reduced ERK phosphorylation in
TNF-α-treated Caco-2 cells, showing that ROCK was possibly acting upstream of ERK.
These results suggest that ROCK may play an integral and complex role in cytokineinduced chemokine production in IEC. Furthermore, since ROCK appears to control the
expression of several pro-inflammatory mediators, ROCK may be a promising
therapeutic target for IBD that merits further research.
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Chapter 1
Introduction: Inflammatory Bowel Disease and
the Role of Intestinal Epithelial Cells in the Mucosal Immune System

Inflammatory Bowel Disease
Inflammatory Bowel Disease (IBD) is a group of chronic, lifelong gastrointestinal
disorders characterized by uncontrolled, relapsing inflammation of the digestive tract [1].
IBD affects approximately 1.4 million people in the Unites States alone and results in
more than $1.8 billion in treatment costs annually [2, 3]. While there are several types of
IBD, a large majority of cases are diagnosed as either Crohn’s disease (CD) or ulcerative
colitis (UC) [4, 5]. In CD, inflammation is discontinuous and may be found throughout
the gastrointestinal tract, while inflammation in UC is contiguous and confined to the
large intestine [1, 5-8]. Inflammation in UC is limited to mucosal and submucosal layers,
whereas in CD, it can also affect deeper tissue layers, which accounts for the higher
incidence in CD patients of perforations in the gastrointestinal wall and of fistulas,
abnormal passages between two gastrointestinal cavities or that open to the skin [9]. UC
and CD share several common immediate symptoms, which include fever, abdominal
pain, vomiting, and bloody diarrhea. Even when well-managed, IBD can also result in
tissue damage leading to ulcerations, perforations, fistulas, or fibrotic adhesions between
adjacent sections of intestine [5-7, 10]. In rare cases, toxic megacolon can occur, a life1

threatening condition in which prolonged inflammation causes paralysis, dilatation, and
necrosis of the large bowel [11]. Additionally, patients who suffer with IBD for several
years have increased risk for intestinal cancers [12].
Despite being the focus of considerable research in recent years, the etiology of
IBD is still poorly understood. However, the current consensus is that IBD results from a
poorly regulated and inappropriate immune response to commensal intestinal
microorganisms [5-8, 13-15].

How this inappropriate response is activated and

prolonged is unclear, although the current evidence indicates that the root cause is
complex and involves combinations of multiple determinants [5-8, 13-17]. IBD is much
more prevalent in industrialized nations [13, 16] and accordingly, was not recognized and
described until the early 20th century [18, 19]. Lifestyle / environmental factors that have
also been linked to IBD include cigarette smoking, diet, oral contraception, and removal
of the appendix [16]. In addition, incidence of IBD has been found to be associated with
reduced diversity and other changes in the intestinal flora [6, 15] as well as with variant
alleles in more than 70 genetic loci [17, 20].
Along with its fundamental causes, a cure for IBD also remains elusive, and after
initial presentation, the disease persists for life, cycling between relapse and remission or,
in a small percentage of cases, producing continuous symptoms [9, 21].

Current

therapies aim to quell symptoms, to induce and maintain remission, preferably without
the use of corticosteroids, and to delay or avoid the need for surgical intervention [22].
Recommended treatment varies depending on the severity of disease, the location and
extent of inflammation, the frequency of remission, and other factors [21, 23]. There is a
variety of anti-inflammatory and immunosuppressive chemotherapeutic agents used to
2

treat IBD [9, 21, 23]. However, their efficacy rates for inducing remission range from
only 30% to 80% [24, 25]. More recently, biologic therapies have been introduced.
Generally speaking, biologics are products derived from or synthesized by living
organisms and often are composed of recombinant proteins. For IBD, there are several
biologics, many of which target pro-inflammatory mediators such as tumor necrosis
factor-α (TNF-α) [25, 26].

These include the anti-TNF-α monoclonal antibodies,

infliximab, adalimumab, golimumab, and certolizumab pegol, which have similar
efficacies as non-biologics, inducing remission in only 40 – 60% of cases. While longterm use of corticosteroids is considered to carry the highest risk for severe, even lifethreatening, side-effects [27], all of these treatments can be accompanied by serious
adverse sequelae, including increased risks for opportunistic infections and for certain
cancers [21, 23-25].

Furthermore, of those patients responding to the monoclonal

antibody biologics, 25 – 70% experience a loss of response to treatment due to the
production of anti-drug antibodies [21, 26]. On top of that, despite the goal of preventing
the need for surgical treatment, 30 – 40% of ulcerative colitis patients and 70 – 80% of
Crohn’s disease patients still require at least one surgery during the course of their
disease [28].
The current treatments for IBD have many shortcomings, and even those patients
who respond well are burdened with relapsing symptoms and lifelong courses of
medication. The solutions to these problems lie in finding answers to the many questions
that still remain about the causes and progression of IBD. Thus, research that explores
the mechanisms of IBD pathogenesis, including the role that intestinal epithelial cells
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play in inflammation, must continue if improved treatments and ultimately a cure are ever
to be possible.

The Intestinal Mucosa
The innermost layer of the intestine, known as the mucosa or mucous membrane,
surrounds the intestinal lumen and interacts directly with its contents. At 200 to 300 m2,
a surface area greater than a tennis court, the human gastrointestinal mucosa is, by far, the
most extensive bodily surface to contact the external environment [29, 30]. The mucosa
is responsible for nutrient absorption and the secretion of digestive hormones, enzymes,
and other substances. In addition to digestive functions, the intestinal mucosa plays a
role in immunity by providing a physical, chemical, and immunological barrier to the
entry of microorganisms and other pathogenic agents [31].
The overall architecture of the intestinal mucosa differs between the small
intestine and the colon [as reviewed in 32]. In the small intestine, finger-like structures
called villi project into the lumen, greatly increasing the surface area (Figure 1.1A).
Interspersed between the villi are tubular glands called intestinal crypts or crypts of
Lieberkühn. In the colon, villi are absent, while numerous closely spaced crypts extend
into the colonic surface (Figure 1.1B).
In both the small and large intestines, the mucosa is comprised of three layers: the
muscularis mucosae, the lamina propria, and the intestinal epithelium (Figure 1.1). The
muscularis mucosae separates the lamina propria from the submucosa and is composed of
smooth muscle fibers [32]. The lamina propria is mainly comprised of loose connective
tissue interspersed with blood and lymphatic capillaries needed for the transport of
4

nutrients and hormones [32]. Resident within the lamina propria is a diffuse and diverse
population of immune cells including lymphocytes, tissue-specific macrophages,
dendritic cells, and granulocytes [33]. Finally, the intestinal epithelium consists of a
continuous sheet of columnar epithelial cells that covers the entire intestinal surface,
including lining the intestinal crypts.

The epithelium serves as a selective barrier,

allowing for the absorption of nutrients and physiologically important molecules, while
excluding pathological quantities of antigens and organisms [34].

A
Epithelium
Villus
Crypt

Lamina
propria

Muscularis
mucosae

Colonic surface

B
Crypt

Epithelium

Lamina
propria
Muscularis
mucosae

Figure 1.1: An overview of the structure of the mucosa of (A) the small intestine and
(B) the colon.
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The intestinal epithelium is composed of several cell types that play different
roles in intestinal function. These cell types are classified as absorptive epithelial cells
(or enterocytes), enteroendocrine cells, goblet cells, or Paneth cells, all of which are
derived from intestinal epithelial stem cells found at or near the base of intestinal crypts
[35]. Except for Paneth cells, which are located only at the base of the crypt, all other
cells derived from intestinal stem cells continually move upward from the crypt and are
shed while undergoing apoptosis after reaching the tip of the villus in the small intestine
or after reaching the colonic surface. Through this process of rapid turnover, the integrity
of the epithelium is maintained despite the harsh chemical environment and frequent
abrasion during the digestion and passage of intestinal contents [36, 37]. Epithelial
integrity is also maintained by intercellular junctions that tightly bind the cells of the
epithelium together, making it highly impermeable to many substances [34]. Because of
this, specialized, absorptive intestinal epithelial cells (henceforth referred to as IEC) are
required for nutrient uptake, which is performed via transcellular transport in the case of
small soluble molecules and vesicular transcytosis in the case of larger factors [32, 34].
Additionally, IEC of the small intestine have direct involvement in digestion, expressing
membrane-bound hydrolytic enzymes [32].

Also present in the epithelium are

enteroendocrine cells that help regulate digestion and gastrointestinal motility by
producing hormones and other signals such as secretin, cholecystokinin, and serotonin
[38]. The third cell type is the goblet cell. The main function of the goblet cell is the
production of mucins, glycoproteins that are converted to mucus upon secretion [39].
Mucus forms a layer covering the epithelium, lubricating the movement of luminal
contents through the digestive tract, as well as providing a physical buffer that allows the
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diffusion of nutrients while limiting direct contact between the epithelium and luminal
organisms and antigens [32]. Lastly, Paneth cells provide protection and help regulate
the growth of the epithelium. In defense against bacterial invasion, Paneth cells secrete
many protective substances into the intestinal lumen, including antimicrobials, like
lysozyme [40], α-defensins, which are proteins that form pores in bacterial plasma
membranes [41], and TNF-α, an important inducer of inflammation [42, 43]. Normally,
Paneth cells are found only in the crypts of the small intestine in close proximity to
intestinal epithelial stem cells, but they can also be detected in colonic crypts during
disease [41].

The Immunological Function of Intestinal Epithelial Cells
In addition to absorptive and physical barrier functions, IEC also play an
important role in immunity. As the front-line in the intestinal mucosa, IEC are the first
cells to encounter invading pathogens, and thus, IEC must be able to initiate immune
responses to allow for early detection and control of infection. IEC sense pathogen
invasion and infection via pattern recognition receptors [44]. These receptors detect
pathogen-associated molecular patterns, which are molecular components, such as
peptidoglycan, that are characteristic of large groups of pathogens. Additionally, IEC
express receptors for several cytokines, which are low-molecular-weight peptide
signaling molecules that mediate communication between and regulate the activity of
cells participating in immune responses [45]. Among the receptors expressed are those
for interleukin (IL)-1, IL-6, IL-17, TNF-α, and Transforming Growth Factor-β (TGF-β)
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[46]. The expression of these receptors allows for the regulation of IEC immunological
responses and for IEC to take part in immune system signaling networks.
Upon encountering foreign antigens or pro-inflammatory cytokines, IEC respond
in several ways that can advance the inflammatory response or otherwise aid in innate
and adaptive immunity. IEC can produce the antibiotic peptides, β-defensins, and have
been found to secrete many cytokines such as IL-1β, TNF-α, and IL-6. In response to
pro-inflammatory signals, IEC also produce several chemokines, a sub-class of cytokines
that attract and activate leukocytes [47-51]. Those leukocytes can then direct further
immunological responses. Additionally, IEC can play a role as antigen-presenting cells,
expressing major histocompatibility complex class II proteins, co-stimulatory molecules,
and adhesion molecules required for the activation of T cells [as reviewed in 52].

The Inflammatory Response
Upon injury and/or in the beginning stages of infection, the innate immune system
mounts an acute inflammatory response [as reviewed in 45]. This response is a cascade
of protective measures, the goal of which is to control and clear infection while initiating
the healing process. Early in this response, localized vasodilation and increased vascular
permeability allow for the influx of fluid from the capillaries into the affected area and
results in the characteristic edema, heat, and redness of inflammation. After vascular
changes have begun, neutrophils begin to infiltrate the site of inflammation, followed
later by monocytes and lymphocytes.

In order for infiltration to occur, circulating

leukocytes must be able to exit the bloodstream and home in on the affected area.
Chemotactic chemokines, produced in response to IL-1, TNF-α, and other inflammatory
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signals, recruit leukocytes from the bloodstream, which then follow the chemokine
gradients to the site of inflammation. After infiltration, the various types of leukocytes
work in concert with cells already resident at the affected site to mount a wide array of
immunological responses.
The first of the leukocytes to arrive at a new site of inflammation are the
neutrophils, professional pathogen killers that remove invading organisms by
phagocytosis and produce many antimicrobial substances [as reviewed in 53]. Upon
activation at a site of infection, neutrophils undergo the process of respiratory burst in
which oxygen uptake greatly increases leading to the production of multiple toxic
reactive oxygen species, reactive nitrogen species, and hypochlorite.

Activated

neutrophils also undergo degranulation in which the contents of storage vesicles are
released into the extracellular milieu or into phagolysosomes, large vesicles containing
phagocytosed microbes. Neutrophil granules contain many antimicrobial substances,
which include proteins that can permeabilize microbial plasma membranes such as
bactericidal/permeability increasing protein, β-defensins, and cathelicidin. Neutrophils
also secrete proteases, which, in addition to attacking invaders, digest extracellular matrix
and surface proteins on cells in the surrounding tissues.
While neutrophils have a singular purpose, macrophages take on a wider range of
roles in acute inflammation. Macrophages can be stimulated by various combinations of
interferon-γ (IFN-γ), TNF-α and microbial products. Like neutrophils, macrophages
produce a wide array of pro-inflammatory cytokines and are believed to be the main
source of the major inflammatory mediators, IL-1, TNF-α, and IL-6, during acute
inflammation [54, 55]. In addition, macrophages interact with and activate antigen9

specific T cells, which then produce additional cytokines that further the immune
response [54, 56].
In order to defend against the full array of pathogens the human body can
encounter, the adaptive immune system is also activated during inflammation, widening
the variety of possible responses. One of the major types of cells in the adaptive immune
system is CD4+ T lymphocytes (helper T cells), of which there are several subtypes.
Once activated, helper T cells play central roles in the regulation and progression of both
innate and adaptive immune functions. In cell-mediated immunity, type 1 helper T cells
(TH1) activate and orchestrate the activities of several other cell types, including
neutrophils and macrophages (hence the term cell-mediated) [45, 57].

In contrast,

immune functions governed by type 2 helper T cells (TH2) are termed humoral and are
characterized by the increased production of antibodies by B cells and the activation of
eosinophils [57, 58]. Among the other subsets of CD4+ T cells are regulatory T cells
(Treg), which act to limit inflammation by secreting large amounts of anti-inflammatory
IL-10, and also inflammatory T helper 17 (TH17) cells [59]. TH17 cells characteristically
produce the pro-inflammatory cytokine, IL-17, and play an important role in the
progression of inflammation and other immune responses during infection by
extracellular bacteria and fungi [57, 59, 60]. Interestingly, it is because of this role in
inflammation that TH17 cells have been implicated in several autoimmune disorders,
including systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and IBD
[61].
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The Histological and Cellular Pathology of Inflammatory Bowel Disease
Numerous functional abnormalities and morphological changes in IBD-affected
tissues and cells have been identified [62-67]. In the mucosae of IBD sufferers, IEC
exhibit poorly formed microvilli, and the normally smooth surface of the epithelium has
an irregular appearance [67, 68]. In inflamed tissues, damage to the epithelium due to
increased IEC apoptosis is repaired through restitution, a process in which IEC rapidly
spread and move into damaged or denuded areas to close any gaps [67, 69-71].
Restitution occurs independently of cell proliferation and on a much quicker time scale.
Consequently, as the IEC compensate to cover more area and maintain epithelial
integrity, the thickness of the epithelium is reduced, and the IEC lose their columnar
shape and become somewhat cuboidal [66-68, 72]. Also accompanying these changes
are a reduction or loss of the protective mucus layer, an increase in epithelial
permeability, and often, the abnormal presence of Paneth cells in the colonic epithelium
[41, 66, 67]. If inflammation persists unchecked, continued damage to the epithelium
outstrips the ability of restitution and IEC proliferation to maintain the epithelial barrier
and erosion of the epithelium occurs, leading to ulcerations involving subepithelial and,
potentially, submucosal tissue layers [66, 67].
As previously described, the normal, non-inflamed intestinal mucosa contains a
diverse population of leukocytes, including dendritic cells, granulocytes, tissue-specific
macrophages, and various subsets of mucosal-homing lymphocytes.

Under normal

conditions, these leukocytes are responsible for immune surveillance, maintaining
tolerance to intestinal microbiota, and activating defenses against pathogens when
needed. However, in IBD, there is a marked increase in the number of immune cells in
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the mucosa due to an influx of activated, pro-inflammatory leukocytes [6, 73]. This
influx includes neutrophils, eosinophils, mast cells, macrophages, plasma B cells, as well
as CD- or UC-specific profiles of effector T lymphocytes (TH1, TH2, TH17, Treg, CD8+
cytotoxic T cells, and natural killer T cells) [6, 7, 74]. These cells are targeted mainly to
the lamina propria [6]. However, during active inflammation, neutrophils are also found
within the epithelium and often transmigrate into the intestinal lumen and particularly
into the crypts where they can cause cryptitis and crypt abscesses, both of which are
indicators of advanced inflammation [66, 67, 75].

With the increased numbers of

activated leukocytes in the mucosa also comes the increased production of several proinflammatory cytokines, including chemotactic chemokines [62], IL-1β, and TNF-α [7678].

IL-1β and TNF-α: Major Mediators of Inflammation
The cytokine, Interleukin-1, plays an important and central role in the initiation
and progression of immune responses. Interleukin-1 consists of two isoforms coded by
two homologous genes: IL-1α and IL-1β. IL-1α is produced by many cell types as either
a membrane-bound or cytoplasmic protein and is rarely released into the extracellular
fluid, except when cells undergo necrosis or rupture [79, 80]. Thus, IL-1α is mainly
involved in the immune response to cell death from non-pathogen-related causes such as
trauma or ischemia [79, 80]. In contrast, IL-1β is a secreted protein that plays a central
role in the response to pathogens and is a major mediator of inflammation in general [7982]. While macrophages are the main source of IL-1β, secretion of IL-1β has also been
observed in IEC, dendritic cells, microglia, fibroblasts, smooth muscle cells, and several
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other cell types [50, 79-81].

Not surprisingly, considering its important role in

inflammation, IL-1β has been found to be involved in numerous autoimmune and
autoinflammatory diseases [79-83].
As it is pleiotropic, IL-1β has been found to elicit a wide array of local and
systemic pro-inflammatory and pro-healing effects [79-83].

In target cells, IL-1β

stimulation results in the expression of a multitude of genes [81-83]. Among these genes
are those that code for matrix metalloproteinases responsible for the degradation of the
extracellular matrix and the resorption of bone and cartilage that can occur during
prolonged inflammation [79, 81-83].

IL-1β also induces the expression of surface

adhesion molecules, such as vascular cell adhesion molecule-1 by endothelial cells,
which are required for the extravasation of leukocytes from the bloodstream [79-83].
Perhaps more importantly, however, IL-1β initiates a cascade of inflammatory signals by
inducing the expression of several other cytokines, including chemokines [79-83], IL-6
[79, 84], IL-23 and IL-17 [79-81], and even IL-1β itself [79, 80].

Some of these

cytokines can, in turn, stimulate the production of further downstream cytokines, while
some are involved in the differentiation, proliferation, and activation of other leukocytes
[79-81]. Furthermore, IL-1β is also involved in inducing fever and in angiogenesis and
can indirectly cause the release of corticosteroids involved in stress response [79, 80, 83].
While it is clear that IL-1β is an important pro-inflammatory mediator, it is
TNF-α that truly plays a central role and has even been termed the “master regulator” of
inflammation [85]. TNF-α is produced as a membrane-bound homotrimeric protein that
is released into the intercellular milieu by proteolytic cleavage [86]. Macrophages are
thought to be the main source of TNF-α in the human body [86, 87]. However, under
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pro-inflammatory conditions, several other cells types are known to produce TNF-α,
including IEC [50]. TNF-α is a pleiotropic cytokine with many different effects in a wide
spectrum of physiological contexts. Perhaps most importantly, TNF-α plays a critical
role in the defense against pathogens [86, 88]. Because of this role in the response to
pathogens, TNF-α has also been implicated in septic shock with some studies showing
TNF-α to be the primary driver of host damage [86, 88]. TNF-α has been also been
implicated in several other physiological processes and conditions, including cachexia,
liver destruction during acute hepatotoxicity, rheumatoid arthritis, IBD, and, under
certain circumstances, it can cause tumor necrosis [86, 88, 89].
This profusion of physiological activities arises from both the direct and indirect
effects that TNF-α exerts on a wide array of cell types. These effects are mediated by
two TNF-α-binding receptors: TNFR1 and TNFR2. Expression of TNFR2 is highly
regulated and is only found in a limited number of cell types, including endothelial cells,
thymocytes, T lymphocytes, and astrocytes, whereas TNFR1 is expressed ubiquitously
and in a constitutive manner [86, 90]. It is this pervasive expression of TNFR1 that
accounts, at least in part, for the pleiotropy that TNF-α possesses, and the binding of
TNF-α to its receptors can evoke a multitude of cellular responses. For instance, under
certain cellular contexts, TNF-α can induce cell death through either apoptosis or
necroptosis [87, 90], while more commonly, TNF-α induces the expression of a range of
genes involved in such processes as cell proliferation, cell survival, and the production of
pro-inflammatory cytokines [86, 87].
Not surprisingly, there is a complex regulatory relationship between TNF-α and
IL-1β, each affecting the action of the other in various ways. For example, neutralization
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of TNF-α with antibodies was found to significantly reduce the production of IL-1β in
cultures of synoviocytes isolated from rheumatoid arthritis patients, indicating that
TNF-α induces IL-1β secretion in these cells [91]. TNF-α has also been found to affect
IL-1 signaling by downregulating IL-1 receptor I (IL-1RI) expression in the rat IEC-6
cell line [92], while it was found to upregulate both IL-1β production and IL-1RI
expression in bone marrow stromal cells [93]. Furthermore, TNF-α and IL-1β are known
to act together synergistically [94], for instance, in the production of cytokines in IEC
[95-97].

Chemokines
Chemokines are a superfamily of cytokines that consist of small (~8 – 14 kDa),
soluble, heparin-binding proteins that have several functions in host defense and
maintenance of the immune system [98]. The chemokine superfamily has been classified
into four families based on the configuration of two highly conserved N-terminal cysteine
residues [98]. These are the CC, CXC, CX3C, and C families. The CX3C and C families
are minor groupings with one and two members, respectively, whereas the CC and CXC
families contain the bulk of the more than fifty chemokine members [98, 99]. While
there is no hard rule regarding what leukocytes are affected by any given family of
chemokines, neutrophils are mainly acted upon by CXC chemokines, while macrophages
and monocytes are predominantly acted upon by CC chemokines [100, 101].
Furthermore, chemokines are promiscuous, some interacting with more than one receptor
and most affecting multiple cell types [100].
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Many chemokines are directly involved in inflammation, while some have
functions in immune system homeostasis and other processes [as reviewed in 98, 99, 100,
101].

Generally speaking, chemokines guide leukocyte traffic by acting as

chemoattractants.

For pro-inflammatory chemokines, this is their primary purpose,

drawing leukocytes to sites of infection or inflammation. Due to the transient nature of
host defense, pro-inflammatory chemokines are expressed as needed and are induced by
host signals, like TNF-α, or by the detection of foreign antigens. In addition to providing
leukocytes direction to sites of inflammation, pro-inflammatory chemokines also play a
key role in the extravasation of leukocytes from the bloodstream by inducing the
activation of integrins on the surface of leukocytes, which allows the leukocytes to attach
to adhesion molecules expressed by vascular endothelial cells and then exit the blood
vessel via diapedesis [62, 101].

Some chemokines also further the inflammatory

response by stimulating leukocytes to release of hydrolytic enzymes or to undergo
oxidative burst, the generation of reactive oxygen species and reactive nitrogen species
[45, 62].
The first chemokine to be discovered was CXCL8, also known as interleukin-8
[102]. It was originally found to be chemotactic for neutrophils. However, it has also
been reported to induce homing in monocytes, basophils and CD4+ and CD8+ T cells as
well [103-105]. Secretion of CXCL8 is highly regulated, and little to none is generated
unless cells are stimulated [106]. When stimulation does occur, production of CXCL8
increases rapidly, and large amounts can be secreted in a relatively short time [106, 107].
Stimuli that induce CXCL8 expression include cytokines, such as TNF-α and IL-1β,
pathogen-associated molecular patterns such as lipopolysaccharide (LPS), and cellular
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stress [106]. CXCL8 is widely produced and has been observed in IEC, monocytes,
neutrophils, endothelial cells, and many others [106, 108].

In addition to inducing

homing, CXCL8 also acts as an activator of neutrophils, prompting vascular adhesion and
extravasation, degranulation, and respiratory burst [45, 103]. In addition, CXCL8 was
the first chemokine found to be angiogenic [109] and has been shown to promote
re-epithelialization in cutaneous and intestinal wounds [101, 108, 110, 111].
CCL2, previously known as monocyte chemotactic protein-1, is another important
chemokine. Like CXCL8, CCL2 is expressed by a wide variety of cells including IEC
[62], other epithelial cells, fibroblasts, smooth muscle cells, endothelial cells, astrocytes,
and monocytes [112]. Production of CCL2 is also induced by a similar profile of stimuli
to that which induces CXCL8, which includes TNF-α, IL-1, IL-4, IFN-γ, LPS, and
cellular stress [112].

Perhaps the most important chemotactic targets of CCL2 are

macrophages and monocytes, which are also a major source of this chemokine [112]. In
addition, CCL2 also recruits natural killer cells, activated T cells, and immature dendritic
cells to sites of inflammation [62] and can participate in angiogenesis by stimulating
endothelial cell migration and inducing the expression of vascular endothelial growth
factor [112].
Whereas some chemokines are inducible and pro-inflammatory, like CXCL8 and
CCL2, and some are constitutively produced and homeostatic, a few chemokines are both
[101]. One such example of a dual-capacity chemokine is CCL20, which was previously
known as macrophage inflammatory protein-3α. CCL20 is chemotactic for T cells,
B cells, and immature dendritic cells [101]. Generally, it is expressed constitutively in
and near secondary lymphoid tissues, but not in primary lymphoid tissues or the spleen,
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which is indicative of its role in the trafficking of unactivated leukocytes to areas of
immune surveillance [113]. In the small intestine, IEC produce CCL20 in order to direct
immature dendritic cells and lymphocytes to the subepithelial dome of the Peyer's
patches and of lymphoid follicles and to the lamina propria in general [101, 113]. Under
inflammatory conditions, CCL20 is produced not just at higher levels by cells that
normally express this chemokine but also by many inflammation-related cell types,
including endothelial cells, neutrophils, macrophage, dendritic cells, natural killer cells,
B cells, and TH17 cells [113-115]. As this array of cell types would suggest, CCL20 is
induced by a wide variety of pro-inflammatory mediators, such as TNF-α, IL-1β, IL-17,
and IFN-γ [113].

Cytokines in IBD
One of the primary characteristics of IBD is the aberrant production of proinflammatory cytokines [116]. Because of its central role in inflammation, the cytokine
TNF-α has received much attention, and several studies have measured TNF-α in IBD
patients. Elevated levels of TNF-α have been detected in stool [117, 118] and blood
serum [119] from patients with active disease. Plus, increased numbers of TNF-αproducing cells have been found in IBD-affected tissues [120, 121] with TNF-α-positive
cells located mainly in the lamina propria and in the submucosa [121]. More commonly,
studies have measured TNF-α secretion by enzyme-linked immunosorbent assay (ELISA)
and have found significantly elevated levels of TNF-α spontaneously produced by
cultured biopsies from IBD patients [77, 122-124] and by lamina propria mononuclear
cells isolated from IBD patients [78]. Some of those studies also found elevated levels of
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the pro-inflammatory cytokines IL-1 and IL-6 in IBD specimens [77, 78, 122], although
McCormack et al. [124] only found elevated levels of TNF-α and IL-6 in CD-affected,
but not UC-affected, tissues. Moreover, elevated levels of TNF-α, IL-1β, and IL-6
production have been found even in non-inflamed tissues of IBD patients [77, 78],
suggesting that cytokine imbalance may be a prerequisite for active disease.

This

imbalance also has implications in the progression of IBD, as the number of TNF-αproducing cells has been found to correlate with the severity of inflammation in CD
[120]. Additionally, increased levels of TNF-α and IL-1β were measured in the rectal
mucosal fluid of IBD patients, and levels of each also correlated separately with
sigmoidoscopic scores, clinical scores, and histological scores of disease activity [125].
Biologics are the newest generation of drugs. Not surprisingly, those that are
used in the treatment of IBD target the aberrant production of cytokines, particularly
TNF-α. The currently approved drugs are mainly recombinant anti-TNF-α monoclonal
antibodies and are believed to work by neutralizing soluble TNF-α, by inducing apoptosis
in activated inflammatory cells, and by increasing the production of anti-inflammatory
molecules [126]. The biologics approved for use in the United States are infliximab,
adalimumab, certolizumab pegol, and golimumab [127]. Another anti-TNF-α agent,
etanercept, which is a fusion protein consisting of the binding portion of the TNF
receptor 2 (TNFR2) and the Fc domain of the IgG1 antibody, failed clinical trials for IBD
despite being approved for rheumatoid arthritis and having a similar efficacy as
adalimumab for that disease [126]. Aside from targeting TNF-α, two biologics that target
integrins, natalizumab and vedolizumab, have been approved [127]. These bind to the α4
integrin subunit and the α4β7 integrin, respectively, and block the vascular adhesion and
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extravasation of lymphocytes, preventing the progression of inflammatory infiltrate into
intestinal tissues. In addition, several treatments that target cytokines other than TNF-α
are currently approved or are in development. These include the IL-12- and IL-23targeting ustekinumab, which was recently approved for the treatment of CD [128];
tocilizumab that targets IL-6, which is in clinical trials; and four agents that target IL-13,
also in trials [127].
The anti-TNF-α therapies listed above all have similar efficacies and induce
remission in 40 - 60% patients [23, 25, 26, 126], and similar rates of remission have been
reported for the anti-IL-12/IL-23 ustekinumab as well [129]. Unfortunately, this leaves
approximately 50% of patients as primary non-responders, although lack of response to
one agent does not necessarily predict a lack of response to others [23]. In addition,
secondary loss of response also occurs in 70% of those who initially respond to the antiTNF-α drugs [26]. This is due to the immunogenicity of these recombinant proteins,
which leads to the formation of anti-drug antibodies by the patients' immune systems.
Furthermore, in the case of infliximab, pre-existing anti-drug antibodies have been found
in naïve patients [130], which may explain at least a percentage of primary nonresponders and suggests the possibility of antidrug antibodies to other agents as well.
Despite these shortcomings, these agents are efficacious for many patients, yet are not
without potential side effects, such as anaphylaxis [23], increased risk of opportunistic
infections [9, 23], and increased risk for hepatosplenic T cell lymphoma in young patients
[131]. Clearly, these treatments are not a panacea, and more research is needed if they
are to be improved of if new therapies are to be developed.
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Pro-inflammatory cytokines are not alone in their dysregulation in IBD.
Abnormal production or dysfunction in the signaling mechanisms of several antiinflammatory mediators is also found in IBD. For example, IL-1 receptor antagonist
(IL-1Ra) is a soluble protein that attenuates IL-1 signaling by competitive binding to
IL-1RI [81]. In IBD, increased levels of IL-1Ra have been found in mucosal biopsy
specimens [132] and in stool samples [118]. More significantly, however, the ratio of
IL-1Ra to IL-1 was shown to be greatly reduced in both mucosal biopsies and the stool
from IBD patients, suggesting an increased rate of unimpeded IL-1 signaling in these
patients. Furthermore, one polymorphism of the IL-1Ra gene has been associated with a
higher risk for UC [133]. Other anti-inflammatory mediators that are dysregulated in
IBD include the soluble forms of TNFR1 and 2, which are formed by proteolytic
cleavage of the extracellular domains of these receptors [134]. Once cleaved, the soluble
forms then act as decoy receptors for TNF-α. Accordingly, serum concentrations of both
soluble receptors are elevated in both CD and UC [134, 135] and correlate with disease
activity [134].

Another anti-inflammatory mediator is the cytokine IL-10, which

downregulates antigen presentation and pro-inflammatory cytokine secretion in
leukocytes [116]. Measurements of serum levels for IL-10 showed increases of IL-10 in
patients with active disease [136], and one study found that expression of IL-10 mRNA
was upregulated in intestinal tissues from patients with active CD and UC as well as
inactive UC [137]. In addition, loss-of-function mutations in the IL-10 receptor have
been associated with early onset of IBD in children [138]. Similarly, IL-10 knockout is
sufficient for the development of chronic intestinal inflammation in mouse models of
IBD [116]. The anti-inflammatory cytokine TGF-β1 also exhibits defective signaling in
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IBD [116, 139]. Tissues and cells isolated from IBD patients are insensitive to TGF-β1
and treatment with TGF-β1 fails to elicit normal inhibition of the production of proinflammatory cytokines [139]. Despite these findings, it is still unclear what functional
consequences the aberrant regulation of these anti-inflammatory mediators has in the
pathogenesis of IBD, although some work has been done on developing IL-10 as a
treatment [140], and a therapy to restore TGF-β1 signaling is currently undergoing trials
[127].
Chemokines are also found to be dysregulated in IBD.

It is believed that,

generally speaking, chemokines contribute to the pathophysiology of IBD by promoting
the activation and influx of leukocytes into intestinal tissues [62]. The increased numbers
of inflammatory cells then produce further chemokines that draw additional leukocytes,
resulting in a positive feedback loop. Many chemokines are found at elevated levels in
IBD, and among them are the neutrophil-attracting CXCL1, CXCL2, CXCL5, CXCL6,
and CXCL8 chemokines [14, 141]. Also included are monocyte/macrophage attractants,
such as CCL2, CCL3, CCL4, CCL5, CCL7, and CCL8 [14, 62, 74]. Several of the latter
group also induce homing in T cells, B cells, and dendritic cells as well [62]. CXCL8 is
of particular importance and has been the focus of much study. In addition to overall
increased production of CXCL8 in IBD [74, 141-143], one study found increased
expression of CXCL8 mRNA specifically in ulcerated regions of resected bowel
specimens [144]. Furthermore, levels of CXCL8 have been found to correlate with the
severity of inflammation in IBD [143, 144] and, as would be expected, to correlate highly
(r = 0.95) with neutrophil numbers in colonic tissues of IBD patients [143]. For CCL2,
increased mRNA expression and protein production has been found in macrophages,
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smooth muscle cells, and endothelial cells of the lamina propria and submucosa of IBDaffected intestinal tissues [145, 146], as well as in IEC [146]. Another chemokine that is
upregulated in IBD is CCL20, which is normally homeostatic, constitutively expressed,
and attracts T cells and dendritic cells [62, 101, 141]. Experiments using both fluorescent
confocal microscopy [114] and immunohistochemistry [115] have shown that IEC are the
main source of CCL20, expressing the protein in normal tissues and at elevated levels in
inflamed tissues. Furthermore, CCL20 protein levels in tissue homogenates were found
to be elevated in patients with active CD and UC as well as from patients with inactive
CD [115].

IEC in inflammation
Not only does the intestinal epithelium form a physical barrier to the entry of
bacteria and other luminal organisms into the body, but the cells of the epithelium also
act as direct participants in immune responses. In vitro experiments with IEC have
shown that infection with intracellular pathogens stimulates the production of
chemokines by IEC [48, 147]. Furthermore, IEC express several pattern recognition
receptors, including toll-like receptors and nucleotide-binding oligomerization domain
protein 2, which allow IEC to directly sense the presence of pathogen components [44].
After binding of their respective ligands, these receptors subsequently activate the
transcription factors nuclear factor κB (NF-κB) and activator protein-1 (AP-1), among
others, and induce the expression of pro-inflammatory genes, although some toll-like
receptor activity has been linked to immune tolerance as well [44]. In addition to directly
reacting to luminal organisms, IEC also participate in the immune system by responding
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to many cytokines. One study showed that both isolated normal rat IEC and the IEC-6
rat cell line expressed IL-1RI mRNA, but not the negative regulator IL-1RII, which is a
decoy receptor [92]. Additionally, Panja et al. [46] found evidence that IEC isolated
from normal human intestinal specimens express receptors for IL-1 as well as for IL-6.
That group also found evidence for TNF receptor expression in HT-29, DLD-1, and
Caco-2 intestinal epithelial cell lines. Similarly, Mizoguchi et al. [148] found that IEC in
normal human tissues express TNFR1, but not TNFR2, while IEC in samples from CD
and UC did express TNFR2. Furthermore, that study also showed that the expression of
both TNFR1 and 2 was upregulated in actively inflamed tissues in a mouse model of
colitis.
IEC react to pathogen challenge or to stimulation with cytokines by upregulating
many genes involved in inflammation, including additional cytokines and adhesion
molecules [147]. For instance, when infected with enteroinvasive bacteria, both the
Caco-2 and the HT-29 IEC cell lines have been found to secrete increased amounts of
CXCL8 and CCL2 [50, 51]. Infected HT-29 cells have also been shown to produce
CXCL1, CCL4, and CCL5 [51] as well as TNF-α and granulocyte/monocyte colony
stimulating factor [50]. The HT-29 and T84 cell lines have also been shown to produce
increased levels of CCL20 in response to bacterial invasion [114].

This array of

cytokine/chemokine responses to bacteria suggests that IEC play an important part in the
inflammatory response versus pathogens. IEC also participate in the progression of
inflammation by responding to pro-inflammatory cytokines, particularly IL-1β and
TNF-α. A third important pro-inflammatory cytokine, IL-6, is produced by the Caco-2
and CCL-241 IEC cell lines when treated with IL-1β or TNF-α [149, 150], and IL-6
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secretion is increased synergistically in IEC-6 and Caco-2 cells when treated with IL-1β
and TNF-α together [96, 97]. Similar to their response to bacterial infection, IEC also
produce a number of chemokines in response to pro-inflammatory cytokines.

For

example, the Caco-2 and HT-29 cell lines are known to secrete CXCL8 when stimulated
with IL-1β or TNF-α [151] or both [51]. Interestingly, and likely not coincidentally,
increased levels of CXCL8 have been found to correlate with increased levels of both
IL-1β and TNF-α in IBD-affected tissues [143]. In addition to CXCL8, HT-29 and
Caco-2 cells have been shown to secrete or express mRNA for CXCL1, CXCL3,
CXCL5, CXCL10, CCL2, CCL4, CCL5, and CCL7 when treated with TNF-α [46, 50,
51]. Elevated amounts of CCL20 are also produced by HT-29, Caco-2, and T84 cells in
response to either IL-1β or TNF-α [114]. Furthermore, one study examined IEC in
intestinal biopsies by immunohistochemistry and found increased expression of CXCL8,
CCL2, CCL3, CCL4, and CCL7 [74], while another study found CCL20 to be
upregulated by IEC in inflamed human mucosae [114].

TNF-α and IL-1 signaling
TNF-α signaling is highly complicated and involves the activation of a network of
intracellular signaling pathways that have not yet been fully elucidated. Similar to other
protein ligands, transduction of the TNF-α signal begins with either of two
transmembrane receptors: the ubiquitously expressed, death-domain-containing 55 kDa
TNFR1 and the 75 kDa TNFR2, which has limited expression (Figure 1.2) [87, 90].
Upon binding of TNF-α to either receptor, assembly of a receptor signaling complex is
initiated and proceeds through the sequential recruitment of several adapter proteins, non-
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degradative ubiquitin ligases, and kinases [as reviewed in 87]. For TNFR1, the primary
event in the assembly of the complex is the direct binding of the TNFR1-associated death
domain protein (TRADD) to the death domain of TNFR1.

This allows for the

recruitment of TNFR-associated factor 2 (TRAF2) and TRAF5. In TNFR2 signaling,
TRAF2 and TRAF5 bind directly to the activated receptor. The binding of additional
proteins to TRAF2 and TRAF5 follows and leads to the downstream activation of
TGF-β-activated kinase 1 (TAK1) as well as the recruitment of the IKK (inhibitor of κ
light chain gene enhancer in B cells (IκB) kinase) complex. TAK1 can then initiate
NF-κB signaling by phosphorylating and activating IKKα and IKKβ, which, in turn,
phosphorylate IκB proteins.
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Figure 1.2: The initial stages of TNF-α signal transduction. A) When TNF-α binds to
the TNFR1 receptor, the resulting conformational change in the receptor initiates the
formation of a complex that starts with the recruitment of TRADD, which, in turn,
recruits TRAF2 and TRAF5. B) Formation of the TNFR2 receptor complex proceeds
similarly to TNFR1 signaling except that TRAF2 and TRAF5 bind directly to the
activated receptor. C) Formation of either receptor complex leads to the activation of the
TAK1 kinase which then activates the IKK complex by phosphorylating IKKα and IKKβ.
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Aside from the NF-κB pathways, TNF-α is also known to activate several other
signaling pathways (Figure 1.3). After its TNF-α-induced activation, TAK1 may also
participate in additional downstream events and may act as the mitogen-activated protein
kinase kinase kinase (MAP3K) for either the c-Jun N-terminal kinase (JNK) pathway or
the p38 mitogen-activated protein kinase (MAPK) pathway, which are both activated by
TNF-α [86, 87]. However, the exact role of TAK1 is as yet unclear, and it may be that
TAK1 acts further upstream as an activator of other MAP3Ks, such as MAPK/ERK
kinase kinase 1 (MEKK1) or apoptosis signal-regulating kinase 1 (ASK1) [86, 90]. The
ERK (extracellular signal-regulated kinase) pathway is also activated by TNF-α, albeit in
some circumstances, it seems this activation may be indirect via an autocrine loop [86,
152]. Additionally, there have been reports of TNF-α inducing the phosphatidylinositol
3-kinase (PI3K)/Akt pathway [153, 154].
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Figure 1.3: Signaling pathways activated by TNF-α. TNF-α signaling is highly
complex and results in the simultaneous activation of multiple signaling pathways. These
include NF-κB and the three major MAPK pathways: JNK, p38 MAPK, and ERK.
Under some conditions, TNF-α also activates the PI3K/Akt pathway.
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IL-1β signaling is similarly complex, and many of the same pathways are
activated as with TNF-α. In target cells, IL-1β stimulation results in the simultaneous
activation of several transcription factors, including, but not limited to, AP-1, NF-κB, and
NF-IL6, and the subsequent expression of a multitude of genes [81-83]. The IL-1β
signaling cascade begins with the binding of IL-1β to its cognate receptor IL-1RI,
followed by the immediate recruitment of the IL-1 receptor accessory protein. This
accessory protein acts as a coreceptor and is required for signaling to occur through the
nascent receptor complex [81-83]. Upon this complex are recruited several other adapter
and activator proteins, such as the IL-1 receptor-associated kinases and myeloid
differentiation factor 88 [81, 82, 155]. Similar to TNF-α signaling, the progression of the
receptor complex assembly leads to the activation of TAK1 [82]. The exact functions
held by TAK1 in IL-1β signaling are still not completely clear. However, TAK1 has
been identified as a mediator of IL-1β-induced NF-κB signaling [82]. In addition, one
study showed that TAK1 is required for the activation of both the NF-κB and JNK
pathways in vitro [156], and TAK1 has also been implicated in the upstream events in
IL-1β-induced p38 MAPK activation [82]. Furthermore, IL-1β is known to activate all
three MAPK pathways, including the ERK pathway as well [81, 83, 155].
As one of the main downstream intracellular effectors of both TNF-α and IL-1β,
NF-κB plays a major role in cytokine-induced inflammation. NF-κB is also involved in
many other processes and was first discovered as a regulator of the immunoglobulin κ
light chain gene in B cells, hence the κB in its name [157, 158]. NF-κB is a family of
transcription factors that bind to DNA elements known as κB sites and regulate the
expression of over four hundred genes [159]. These include the genes for IL-1β, TNF-α,
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CXCL8 [158, 160], CCL2 [112], and CCL20 [113]. NF-κB also regulates adhesion
molecules such as intercellular adhesion molecule-1 and vascular cellular adhesion
molecule-1 [158, 160], and inflammation-related enzymes such as cyclooxygenase-2,
inducible nitric oxide synthase, and matrix metalloproteinases [159]. Also among the
genes under the control of NF-κB are several genes with anti-apoptotic activity [159].
These affect the development of dendritic cells, T cells and B cells as well as increasing
the survival time of activated neutrophils, which must operate in relatively toxic, proapoptotic conditions. In addition, NF-κB induces genes involved in cell growth and in
the development of lymphoid organs, which includes regulating homeostatic cytokines
that control the proliferation and differentiation of lymphocytes [157, 159].
In mammals, the NF-κB family of transcription factors consists of homodimers
and heterodimers of five different gene products: NF-κB1, NFκB2, c-Rel, RelB, and
RelA (a.k.a. p65) [as reviewed in 157, 158, 159]. Of the five, both NF-κB1 and NF-κB2
do not contain transactivation domains and thus, must dimerize with one of the remaining
three members in order to activate transcription. When unactivated, NF-κB dimers reside
in the cytoplasm and are sequestered there by the binding of inhibitory IκB proteins,
which eclipse the nuclear localization signals on the NF-κB proteins, preventing their
translocation to the nucleus (Figure 1.4). IκB proteins consist of IκBα, IκBβ, IκBγ, IκBε,
and Bcl-3 with IκBα being the most abundant. Upon activation of the pathway, IκB
proteins are phosphorylated, then ubiquitinated, and rapidly degraded in the proteasome.
This leaves NF-κB free to translocate to the nucleus and initiate transcription.
Interestingly, one of the transcriptional targets of NF-κB is IκBα itself. This allows for a
negative regulatory mechanism in which the degradation of IκBα and release of NF-κB is
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followed some time thereafter by a rise in IκBα levels and the subsequent resequestration
of NF-κB in the cytoplasm. Alternatively, dimers containing NF-κB2 are not bound by
IκB proteins as this protein serves the same purpose as IκB. When activated, the 100 kDa
NF-κB2 undergoes ubiquitination- and proteasomal-dependent cleavage to a 52 kDa

Signaling from
various stimuli
(e.g. TNF-α )

NEMO
(IKKγ)

(p52) form, allowing the p52-containing NF-κB dimer to then translocate to the nucleus.

IKKα
Ub

IKKβ

Ub
Ub
P

P

IκBα

IκBα

IκBα

NF-κB

NF-κB

NF-κB

Ub

Ub

NF-κB
Ub

Ub

Ub

Nuclear membrane

Transcription
Figure 1.4: The mechanism of NF-κB activation. NF-κB is held in the cytoplasm by
the binding of an inhibitory IκB protein, such as IκBα. Upstream signals from a variety
of stimuli activate the IKK complex, which then phosphorylates IκBα, marking it for
polyubiquitination and subsequent proteasomal degradation. This frees the NF-κB dimer,
allowing it to translocate into the nucleus and initiate transcription of a wide array of
genes.
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Directly upstream of IκB proteins in the NF-κB signaling cascade is the IKK
complex (IKK) [as reviewed in 158, 159]. The IKK complex consists of three proteins:
IKKα and IKKβ, which are the catalytic subunits, and the regulatory scaffold protein
known as NF-κB essential modulator (NEMO a.k.a. IKKγ). The purpose of this complex
is to phosphorylate IκB proteins, marking them for degradation. Two mechanisms of
NF-κB activation by IKK have been discovered, the canonical and non-canonical
pathways.

In the canonical pathway, NEMO and IKKβ are required for the

phosphorylation of IκB proteins, whereas the non-canonical pathway is dependent on
IKKα in the phosphorylation of NF-κB dimers containing the 100 kDa NF-κB2.
Upstream, both TAK1 in the canonical pathway and NF-κB-inducing kinase (NIK) in the
non-canonical pathway have been identified as activators of IKK, although questions still
remain regarding whether these are the only two. Thus, to summarize the canonical
pathway, TAK1 activates the IKK complex, which phosphorylates IκB proteins. This
leads to the ubiquitination and degradation of IκB proteins and the release of NF-κB,
which then translocates to the nucleus and induces various genes. The non-canonical
pathway exhibits a similar pattern except that NIK is the upstream activator and it is
NF-κB2, instead of a separate IκB protein, which is cleaved to allow for translocation of
NF-κB.
Another target of both TNF-α and IL-1β signaling is JNK, a member of the
MAPK family of signaling kinases. JNK controls a wide array of cell activities, such as
apoptosis, cell differentiation, cell growth, inflammation, and other immune responses
[161]. JNK is actually a group of kinases coded by three genes, JNK1, JNK2, and JNK3,
each with four splice variants for a total of twelve possible isoforms [162]. JNK1 and
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JNK2 are expressed ubiquitously, while expression of JNK3 is limited to the heart, brain
and testes [163]. Research has shown that each isoform exhibits different substrate
affinities [163, 164]. However, the specific roles of each of the different variants of JNK
are still poorly understood [161].
The activation of the JNK signaling cascade begins with the activation of a
MAP3K by cellular stress or inflammatory stimuli (Figure 1.5) [162]. Several MAP3Ks
for JNK have been identified and include MEKK1 - 4, ASK1, ASK2, and possibly TAK1
[162, 163]. Following activation, the MAP3K then phosphorylates one of the two known
MAPK kinases (MAP2K) for JNK, MKK4 or MKK7, which in turn, phosphorylate and
thus activate JNK [162].

The components of the JNK cascade are organized into

signaling cassettes by the binding of a MAP3K, a MAP2K, and JNK to scaffold proteins,
which are mainly of the JNK-interacting protein (JIP) family for inflammatory cytokine
signaling [162, 165]. There are several JIP proteins, each with its own specific docking
sites, allowing for the assembly of specific combinations of signaling components. This
allows for control of context-specific responses to various stimuli.

In addition to

dedicated scaffold proteins, the MAP3K MEKK1 can, itself, act as a scaffold, recruiting
and binding MKK4 and JNK to form a signaling cassette [165].
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Figure 1.5: JNK and AP-1 signaling. Stress or inflammatory signals initiate signal
transduction through the JNK pathway by first activating a MAP3K. There are several
kinases known to act as a MAP3K for the JNK pathway, such as MEKK1, ASK1, and
possibly TAK1. Once activated, the MAP3K then phosphorylates either MKK4 or
MKK7, depending on which has been recruited by the scaffold protein (e.g. JIP).
MKK4/7 then phosphorylates JNK, which can subsequently translocate to the nucleus
and activate transcription factors such as AP-1. AP-1 consists of hetero- and homodimers
of Jun, Fos, and ATF proteins. JNK can phosphorylate Jun and ATF proteins, but not
Fos. The resulting activated AP-1 dimers then initiate transcription.
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Once activated, JNK can phosphorylate a wide variety of substrates, but perhaps,
the most important targets are AP-1 proteins (Figure 1.5).

AP-1 is a group of

transcription factors consisting of homodimers and heterodimers of Jun (e.g. c-Jun), Fos,
and activating transcription factor (ATF) proteins [166]. As its classic substrate, c-Jun is
phosphorylated by JNK leading to increased transactivation ability. Phosphorylation of
c-Jun by JNK also inhibits its ubiquitination resulting in its stabilization via reduced
proteasomal degradation [161].

Similarly, JNK also phosphorylates ATF proteins,

enhancing transcriptional activity [163]. Along with AP-1, JNK also activates other
transcription factors, such as Elk-1, FOXO4, NFAT, and p53 [161, 163], and thus,
regulates the expression of many genes, including the genes for TNF-α, CXCL8, vascular
endothelial growth factor, c-Jun, collagenase-3, and aquaporin-1, to name a few [163].
Substrates of JNK also include non-transcription-factor proteins such as the apoptosisrelated proteins, Bim, Bad, and BCL-2, as well as the kinases, Akt and p90RSK (ribosomal
protein S6 kinase) [161].
The first MAPKs to be discovered were the extracellular signal-regulated kinase 1
(ERK1) and ERK2 [167]. The ERK1 and ERK2 genes are highly conserved homologs,
and thus, they function and are regulated in a similar manner under most conditions
[168]. ERK1/2 are primarily activated by mitogens, like epidermal growth factor (EGF)
[168], but also can be activated by stress and inflammatory signals [162]. There are two
MAP2Ks that activate ERK1/2: MAPK/ERK kinase 1 (MEK1) and MEK2 [168].
ERK1/2 are the only known substrates of MEK1/2, and it is believed that the interaction
of MEK with ERK ensures specificity during the signaling cascade. During mitogenic
stimulation of ERK, Raf proteins act as MAP3Ks, phosphorylating MEK, while Ras
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proteins act just upstream, activating Raf in the classic Ras-Raf-MEK-ERK cascade
[168].

In addition, other MAP3Ks have been identified that are involved in ERK

activation during stress or inflammatory signaling, such as MEKK1 [167, 168]. Similar
to JNK, which MAP3K is involved in ERK activation is controlled by scaffold proteins,
of which there are several for ERK [165]. There are approximately 200 known substrates
of ERK [168], which include several transcription factors, such as Elk-1, p53, c-Fos and
c-Jun, as well as downstream effector kinases, like p90RSK, that further the ERK signal
[167]. Through the phosphorylation of its substrates and the subsequent phosphorylation
of substrates by effector kinases, ERK regulates a wide variety of cellular processes, for
example, proliferation, differentiation, survival, and motility [167].

Rho and Rho-associated coiled-coil containing kinase
The Rho family of proteins belongs to the Ras superfamily of small GTPases [as
reviewed in 169, 170]. In humans, there are 23 Rho genes, which are further divided into
six subfamilies: Rho, Cdc42, Rac, Rnd, RhoBTB, and RhoT.
consists of RhoA, RhoB, and RhoC.

The Rho subfamily

Like all small GTPases, Rho proteins act as

molecular switches, cycling between an active GTP-bound state and an inactive GDPbound state.

When active, Rho GTPases bind to effector molecules causing a

conformational change in the effectors, thereby activating them or in a few cases,
deactivating them. There are over 70 known Rho effectors, which include many different
types of molecules, including scaffold proteins, phospholipases, phosphatases, actin
regulatory molecules, and several protein kinases. Through these effectors, Rho proteins
regulate many cell activities, such as cell cycle progression, cell morphology and
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polarity, vesicle trafficking, microtubule dynamics, actin cytoskeletal rearrangement,
acto-myosin contractility, and cell migration through the formation and protrusion of
lamellipodia and filopodia. Rho GTPases also alter the expression of genes containing
serum response elements in their regulatory regions through the activation of the serum
response factor transcription factor [170]. Furthermore, Rho is also known to take part in
MAPK signal transduction and can activate both the JNK and p38 pathways [162, 170].
In addition, MEKK1 is known to interact with Rho, raising the possibility that Rho may
also regulate ERK signaling as well [170].
An important effector of Rho is the Rho-associated coiled-coil containing protein
kinase (ROCK) [as reviewed in 171]. ROCK is a serine/threonine kinase and consists of
two evolutionarily conserved homologs with 64% similarity: ROCK1 and ROCK2. Both
ROCK1 and ROCK2 are expressed nearly ubiquitously in humans and are found together
in almost all tissues except the cervix, spleen, thymus, and tongue where ROCK1 is the
sole isoform. The structure of the ROCK protein consists of an N-terminal kinase
domain, a subsequent coiled-coil region containing a Rho-binding domain, and an autoinhibitory region at the C-terminus (Figure 1.6). The auto-inhibitory region interacts with
the kinase domain and prevents its activity by an as yet unknown mechanism. When Rho
binds to the Rho-binding domain, the auto-inhibitory component is released from the
kinase domain, allowing catalytic activity and thus activating ROCK. Activation of
ROCK may also occur in a Rho-independent manner through proteolytic cleavage of the
auto-inhibitory domain.

This occurs during apoptosis when ROCK1 is cleaved by

caspase-3 or when ROCK2 is cleaved by the apoptosis-initiating granzyme B, resulting in

38

constitutively active forms of ROCK and leading to membrane blebbing and formation of
apoptotic bodies.

A
RBD

Rho

CAT
Inh

CAT
Rho
RBD

B

Figure 1.6: A schematic of the structure and activation of ROCK. (A) The structure
of ROCK consists of a catalytic domain (CAT), an inhibitory domain (Inh), and an
intervening coiled-coil domain that contains a Rho-binding domain (RBD). When
ROCK is unactivated, the inhibitory domain binds to the catalytic domain and prevents
its activity. (B) ROCK is activated by the binding of Rho to the RBD, which causes the
inhibitory domain to release from the catalytic domain. (Adapted from Riento and Ridley
[172].)
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One of the main functions of ROCK is the promotion of acto-myosin contractility
[reviewed in 171, 172]. This occurs through regulating the phosphorylation of myosin
light chain (MLC), the regulatory subunit of myosin II. ROCK exerts its effect on MLC
in two ways: first, by the direct phosphorylation of MLC and second, by the inhibitory
phosphorylation of myosin phosphatase target subunit 1, which results in a decreased rate
of dephosphorylation of MLC. Both of these activities lead to higher rates of MLC
phosphorylation and thus increased contractility.

The functional consequences of

ROCK-dependent acto-myosin contractility include the formation of focal adhesions and
stress fibers, the contraction of the cleavage furrow during cytokinesis, membrane
blebbing during apoptosis, and agonist-induced smooth muscle contraction. In addition
to attachment to the substratum at focal adhesions, ROCK also is involved in cell-cell
adhesion through the modulation of tight junctions. Here the role of ROCK is somewhat
ambiguous as ROCK activity can increase or decrease tight junction integrity and
paracellular permeability depending on cell type. ROCK has also been implicated in cell
migration, and although the details of ROCK's involvement have yet to be fully worked
out, it is likely that ROCK promotes contraction at the rear of the cell and regulates the
turnover of focal adhesions as the cell moves forward. Furthermore, ROCK is involved
in signal transduction leading to the regulation of gene expression as well. For instance,
ROCK activity has been shown to attenuate insulin-stimulated phosphorylation of cyclic
AMP response element-binding protein, and ROCK has also been found to mediate
lysophosphatidic acid (LPA)-induced activation of c-Jun [173].
In a recent study, Segain et al. [123] found a link between ROCK and intestinal
inflammation. In one set of experiments, the Segain group found that levels of active,
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GTP-bound RhoA were significantly elevated in inflamed tissues from biopsies from CD
patients compared to non-inflamed tissues from CD patients and compared to control
patients. The same pattern of RhoA activation was also observed in trinitrobenzene
sulfonic acid (TNBS)-induced colitis in rats. Shifting the focus to ROCK, they also
found that treatment with Y-27632, a specific inhibitor of ROCK, significantly reduced
the amount of TNF-α spontaneously secreted by lamina propria mononuclear cells
isolated from both inflamed tissues of CD patients and from TNBS-treated rats,
indicating that ROCK mediates TNF-α production in these cells. In addition, TNBStreated rats that were administered the ROCK inhibitor also scored better on several
histological and physiological measures of inflammation than did control rats, pointing
toward the involvement of ROCK in overall inflammatory processes in the intestine.
Similar to what was seen with mononuclear cells isolated from inflamed tissues, LPS
treatment of peripheral blood mononuclear cells induced RhoA activation and the
production of both TNF-α and IL-1β, and furthermore, TNF-α and IL-1β production was
significantly abrogated by the inhibition of ROCK. ROCK inhibition was also found to
prevent the activation of the NF-κB pathway. In that set of experiments, Segain et al.
showed that in peripheral blood mononuclear cells, treatment with either LPS or TNF-α
stimulated the degradation of IκBα and the translocation of NF-κB to the nucleus, and
both of these effects were blocked by treatment with the ROCK inhibitor, which suggests
that ROCK is required for the activation of NF-κB in these cells. These results, taken
together suggest that ROCK may play a critical role in intestinal inflammation and that
the inflammatory signaling activities of ROCK are mediated by NF-κB. To note, Segain
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et al. focused on inflammation in mononuclear cells and whole tissue samples and did not
examine IEC, which compose a major component of the mucosal immune system.
ROCK has been linked to inflammatory signaling in other contexts as well. For
example, inhibiting ROCK was shown to block the secretion of CXCL8, CCL5, and
CCL8 in peptidoglycan-treated synoviocytes from rheumatoid arthritis patients [174].
ROCK inhibition was also shown to significantly reduce CXCL8 secretion in LPSstimulated cervical stromal cells, and this effect was mediated by NF-κB [175]. Clearly,
ROCK plays a role in inflammatory signaling. However, there is still much to be learned
regarding its cell-specific effects, its stimulus-specific effects, and which signaling
pathways are under its regulatory purview.
Recently, experiments in our laboratory have confirmed a role for ROCK in
inflammatory responses in IEC [176]. When ROCK was inhibited with Y-27632 in the
Caco-2 IEC cell line, there was a significant reduction in IL-1β-induced CXCL8
secretion and mRNA expression as compared to IL-1β-only controls. Likewise, there
was a significant reduction in IL-1β-induced CCL2 secretion and mRNA expression in
IEC-6 cells when ROCK was inhibited. Together, these results suggest that ROCK may
be an important mediator of CXCL8, CCL2, and possibly other chemokines in IEC. In
contrast to the results found by the Segain group [123], the experiments in our laboratory
showed that, in Caco-2 cells, ROCK inhibition had no effect on IL-1β-stimulated NF-κB
activation as the rates of IκBα phosphorylation and degradation were unchanged by
ROCK inhibition and there was no effect on IL-1β-stimulated IKK activation. ROCK
inhibition did have an effect on JNK signaling, however. Inhibiting ROCK in Caco-2
cells and in IEC-6 cells led to a suppression of JNK signaling as shown by a significant
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decrease in IL-1β-induced phosphorylation of p46 JNK and p54 JNK, indicating that
JNK signaling may be under the control of ROCK in IEC. This is in accord with another
study that found that the activation of JNK was mediated by ROCK in the NIH 3T3
mouse embryonic fibroblast cell line, albeit not in response to IL-1β [173]. Taken
together, these results suggest that ROCK may play an important part in inflammatory
signal transduction in IEC and possibly other cell types.
Still, more research is needed if we are to understand IBD, the role that IEC play
in IBD, and the role that ROCK may play in the persistent inflammatory signals that
characterize IBD. From our previous work, we know that ROCK is involved in IL-1βinduced CXCL8 and CCL2 responses in IEC and in IL-1β signaling through JNK.
However, little is known about the role of ROCK in the regulation of other chemokines
or the role of ROCK in the transduction of inflammatory signals other than IL-1β. Since
TNF-α plays a central role in IBD and since IEC are a large component of the mucosal
immune system, we turned our focus to examining the involvement of ROCK in TNF-αinduced responses in IEC. This included investigating the involvement of ROCK in the
production of CXCL8, CCL2, and CCL20, as well as examining the effects of ROCK in
several signaling pathways. Understanding the role of ROCK in IEC may open up new
avenues of research into IBD and may identify ROCK as a potential therapeutic target for
the reduction of inflammation in IBD. A ROCK inhibitor drug could be used alone or as
a complement to offset the shortcomings of current treatments for those who do not
respond well.
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Chapter 2
The Role of the ROCK Kinase in Tumor Necrosis Factor-α-Induced
CXCL8 Secretion in Intestinal Epithelial Cells
1. Introduction
TNF-α is a major pro-inflammatory cytokine that plays a central role in
Inflammatory Bowel Disease (IBD) [177]. Elevated levels of TNF-α have been detected
in the serum [119] and stool [117] of patients affected with IBD, along with a
corresponding increase in the production of TNF-α by cells in the intestinal lamina
propria [78, 120, 121] and the intestinal epithelium [178]. As the frontline defense
against pathogens, the cells of the intestinal epithelium are in constant and intimate
contact with the intestinal contents, and since they are the first to encounter luminal
antigens, IEC likely participate in the inappropriate immune response seen in IBD.
Indeed, increased intestinal epithelial permeability has been implicated in the
development of IBD [179-183], and IEC have been shown to produce several cytokines
and other molecules involved in the progression and maintenance of the inflammatory
response [48, 51, 63, 184-186]. Because of the central role of TNF-α in IBD, it is not
surprising that TNF-α can modulate IEC responses. Accordingly, TNF-α has been found
to stimulate the secretion of CXCL1, CXCL3, CXCL5, CXCL8, CXCL10, CCL2, CCL4,
CCL5, CCL20, granulocyte/monocyte colony stimulating factor, IL-1β, IL-6, as well as
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TNF-α itself by several IEC cell lines [49-51, 97, 114, 150, 151]. While IEC responses to
TNF-α are fairly well characterized, more research is needed to elucidate the intracellular
mechanisms that mediate the actions of TNF-α if new treatments for IBD are to be
devised.
Transduction of the TNF-α signal is highly complex and entails simultaneous
actuation of multiple signaling pathways. Despite this complexity, the regulation of
TNF-α-stimulated gene expression is mainly achieved through the activation of two
transcription factors: NF-κB and AP-1 [187]. NF-κB is ubiquitously expressed and is
involved in a wide array of cellular activities, including growth, survival, differentiation,
cell adhesion, and inflammatory response.

In its unactivated state, the NF-κB

transcription factor is bound by inhibitory IκB proteins, most often IκBα, and is
sequestered in the cytoplasm.
phosphorylation

and

An essential step in the activation of NF-κB is the

subsequent

proteasomal

degradation

of

IκBα.

Upon

phosphorylation and degradation, IκBα releases its binding to NF-κB, allowing the
translocation of NF-κB into the nuclear compartment [158, 160]. Accordingly, studies
with IEC cell lines have demonstrated the TNF-α-induced activation of NF-κB by
showing that IκBα is rapidly phosphorylated and degraded upon TNF-α stimulation and
by detecting increased nuclear localization and promoter binding activity of NF-κB [188191]. Once translocated to the nucleus, NF-κB binds to DNA at κB regulatory sites and
activates the transcription. Among the many TNF-α-induced and inflammation-related
genes that are controlled by NF-κB are IL-1β, TNF-α itself, and several chemokines such
as CXCL1, CXCL8, CCL2, and CCL5 [158, 160].
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The AP-1 family of transcription factors is comprised of hetero- and homodimeric
proteins consisting of combinations of Jun, Fos, and ATF proteins, with the c-Jun/c-Fos
form being the prototypical member of this family [192]. AP-1 members play varied
roles in apoptosis, cell survival, differentiation, proliferation, and inflammation [193195]. An important regulator of AP-1 is JNK, which activates AP-1 by phosphorylating
Jun or ATF proteins in response to many different stimuli, including TNF-α [187, 196].
JNK proteins are coded by three genes, two of which, JNK1 and JNK2, are expressed
ubiquitously [196]. In addition, alternative splicing of JNK genes can yield isoforms of
approximately 46 and 54 kDa, which confers differences in substrate specificity and
provides a mechanism for the selective activation of subsets of AP-1 proteins [164]. In
inflammation, AP-1 activates the transcription of TNF-α, IL-1, IL-6, CXCL8, and CCL2,
among others [107, 194, 195, 197-202].
TNF-α has also been shown to activate p38 MAPK, another signaling kinase that
can modulate AP-1- and NF-κB-directed transcription [187]. For instance, p38 MAPK
has been shown in some cases to phosphorylate ATF2 thereby activating AP-1 [192,
203], while a combination of p38 MAPK and ERK activity has been implicated in
regulating histone acetylation required for NF-κB-dependent transcription in mouse
fibrosarcoma cells [204]. The p38 MAPK also activates Elk-1, a transcription factor
involved in initiating the expression of the c-fos gene [203]. In addition to regulating
transcription, p38 MAPK also affects the expression of many pro-inflammatory genes by
regulating mRNA decay through the phosphorylation of AU-rich element (ARE)-binding
proteins [162, 205, 206]. These ARE-binding proteins then bind to AREs found in the
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non-translating 3' regions of mRNAs and modulate the rate of deadenylation-dependent
mRNA decay.
As the focus of research for many years, the basics of TNF-α signaling are well
established. However, many details regarding the mechanisms of TNF-α-induced gene
expression are still unknown. Particularly which variations in signal transduction exist
across cell types and conditions. This includes the specifics of the regulation of NF-κBand AP-1-mediated gene expression as well as signaling through p38 MAPK and other
kinases.
One potential mediator of TNF-α signaling is the Rho-associated coiled-coil
kinase (ROCK). ROCK is a serine/threonine kinase and exists in two isoforms, ROCK1
and ROCK2, which are coded by two highly homologous genes [172].

ROCK is

activated by the binding of Rho family GTPases and is often associated with cellular
processes that involve acto-myosin contractility, cytoskeletal rearrangement, and cell
adhesion, including motility, stress fiber formation, and membrane blebbing during
apoptosis [170, 172]. However, a recent study by Segain et al. [123] found a link
between ROCK and intestinal inflammation. In that study, inhibition of ROCK reduced
intestinal inflammation in rats with experimentally induced colitis and suppressed the
production of TNF-α by lamina propria mononuclear cells isolated from the treated rats
as well as from patients with CD. Additionally, blockade of ROCK with the chemical
inhibitor Y-27632 prevented TNF-α-induced activation of NF-κB in peripheral blood
mononuclear cells isolated from active-CD tissues. Nwariaku et al. [207] also found a
link between ROCK and inflammation when they showed that inhibiting Rho/ROCK
signaling reduced p38 MAPK activity and abolished ERK activity stimulated by TNF-α
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in human lung microvascular endothelial cells. Taken together, these results suggest that
ROCK may be an important mediator of TNF-α-induced inflammation and that inhibiting
ROCK or its downstream targets may be an effective means for alleviating inflammation
in IBD that merits further research.
Of particular interest is what role ROCK may play in modulating TNF-α
responses in IEC.

The full extent of IEC participation in IBD etiology is unclear.

However, IEC are known to react to inflammatory stimuli by secreting relatively large
amounts of the neutrophil chemoattractant CXCL8 [49, 51], a chemokine found at
elevated levels in IBD [74, 144]. In this way, IEC may contribute to the beginning stages
of IBD pathology by initiating leukocyte influx or may provide a continuous signal that
maintains chronic inflammation. In synoviocytes [174], human cervical stromal cells
[175], and human umbilical vein endothelial cells (HUVECs) [208, 209], ROCK has
been shown to play a part in the regulation of CXCL8 secretion, albeit in response to
stimuli other than TNF-α. Additionally, a recent study in our laboratory showed that the
inhibition of ROCK in an IEC cell line led to the suppression IL-1β-induced CXCL8
secretion and mRNA expression and that this corresponded to decreased JNK, but not
NF-κB signaling [176]. Here we report the results of the first investigation of the
function of ROCK in IEC responses to TNF-α. Similar to our previous findings with
IL-1β, inhibiting ROCK resulted in a significant reduction in the TNF-α-induced
secretion and mRNA expression of CXCL8.

Furthermore, our results show a

concomitant suppression of TNF-α-induced JNK activation, while ROCK inhibition had
no effect on the TNF-α-stimulated activation of the NF-κB and p38 MAPK pathways.
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2. Materials and Methods
2.1 Antibodies.
All antibodies used in this study were obtained from Cell Signaling Technologies
(Beverly, MA). These included rabbit polyclonal antibodies against JNK (recognizing
both p46 and p54 isoforms), p38 MAPK, and β-actin; rabbit monoclonal antibodies
against phosphorylated p38 MAPK (Thr180/Tyr182) and phosphorylated IκBα (Ser32);
and mouse monoclonal antibodies against phosphorylated JNK (Thr183/Tyr185) and
IκBα. Horseradish peroxidase (HRP)-conjugated anti-mouse and anti-rabbit antibodies
(Cell Signaling Technologies) were used for detection.

2.2 Cell culture conditions.
The Caco-2 human colonic cell line was obtained from the American Type Culture
Collection (ATCC HTB-37; Manassas, VA) and cultured in Dulbecco’s modified Eagle’s
medium (DMEM; HyClone Laboratories, Logan, UT) containing 10% fetal bovine serum
(FBS; Gibco, Life Technologies, Grand Island, NY), 3.7 g/L sodium bicarbonate, 2 mM
L-glutamine (Lonza, Walkersville, MD), non-essential amino acids (Lonza), and 25 IU
penicillin with 25 μg/mL streptomycin (Mediatech, Herndon, VA). This medium is
subsequently referred to as FBS-DMEM. Cultures were maintained at 37 °C in a 10%
CO2 humid atmosphere.
Caco-2 cells were cultured in 6-, 12-, or 24-well tissue culture plates coated with
fibronectin (FN).

To coat culture plates, 20 μg/mL bovine plasma FN

(Sigma-Aldrich, St. Louis, MO) in PBS was added to wells at 40 µL/cm2 according to the
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growth area for each well size and incubated for 1 h at 37 °C. The fluid was then
aspirated, and the wells were allowed to dry in a biosafety cabinet under UV illumination
before storage at 4 °C until needed. To seed the plates, cells were removed from culture
flasks by treatment with a trypsin/EDTA solution (Sigma-Aldrich) and centrifuged for
5 – 10 min. The cell pellets were then resuspended in FBS-DMEM, added to wells at the
required densities, and incubated for 1 h at 37 °C to allow for attachment. After this, the
medium was removed, and the cells were treated with or without 40 µM of the Y-27632
ROCK inhibitor (Enzo Life Sciences, Farmingdale, NY) in serum-free DMEM with an
additive premix of insulin, transferrin, and selenium (ITS; BD Biosciences, Bedford,
MA) and incubated for 2 h. This was followed by treatment with either recombinant
human (rh)TNF-α (R&D Systems, Minneapolis, MN) at a concentration of 10 ng/mL or
rhIL-1β (R&D Systems) at a concentration of 1 ng/mL and further culturing as indicated
below. Prior work in our laboratory has shown these concentrations of IL-β and TNF-α
to be optimal for the study of cytokine responses in Caco-2 cells [97].

2.3 Preparation of RNA extracts.
Total RNA was isolated from Caco-2 cells using the Qiagen (Valencia, CA) RNeasy kit
according to the manufacturer’s protocol. Caco-2 cells were added to 6-well plates
(1 × 106 cells/well) and treated with Y-27632 as described above. After 2 h incubation,
the cells were treated with either rhTNF-α or rhIL-1β and incubated for an additional 6 h.
At the end of the incubation period, each well was aspirated to remove the medium, and
the cellular contents were extracted using the lysis buffer supplied in the RNeasy kit.
Lysates were homogenized by several passes through 20- or 21-gauge hypodermic
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needles, and RNA was isolated by transferring the lysates to RNeasy spin columns and
then centrifuging. The columns were then washed with the supplied wash solutions, and
RNA was eluted in RNase-free water. Sample concentration and purity was determined
by measuring A260, A280, and A230 with a NanoDrop 2000 spectrophotometer (Thermo
Scientific, Wilmington, DE).

2.4 Quantification of relative CXCL8 mRNA levels.
Relative mRNA levels were determined using real-time RT-PCR.

First, reverse

transcription was performed using the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA) according to the manufacturer’s protocol.
Briefly, 1 μg of total RNA from each sample was converted to cDNA in a 20 µL reaction
containing 10 µL of RNA sample diluted to 0.1 μg/mL in nuclease-free water, an
additional 3.2 µL of nuclease-free water, 2 µL of the supplied RT buffer, 0.8 µL of dNTP
mix (4 mM final concentration), 2 µL of the supplied mix of random hexamer primers,
1 µL of RNase inhibitor, and 1 µL of MultiScribe reverse transcriptase (50 U /reaction).
Reactions were incubated in a thermocycler for 10 min at 25 °C to allow for primer
annealing, then for 2h at 37 °C for the reverse transcription reaction, followed by 5 min at
85 °C to denature the enzyme.
The resulting cDNA samples were then analyzed by real-time PCR. Each 20 µL
reaction contained 2 µL of cDNA sample, 10 µL of iQ SYBR Green Supermix (BioRad
Laboratories, Hercules, CA), 0.8 µL of 10 µM forward/reverse primer mix, and 7.2 µL
RNase-free water. Human CXCL8 and human GAPDH primer mixes were purchased
from SABiosciences/Qiagen (Valencia, CA). Real-time PCR was performed using a
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BioRad MiniOpticon thermocycler running the following program: 95 °C for 3 min, then
40 two-step cycles of 95 °C for 15 s and 60 °C for 60 s, followed by a melting curve
determination. Relative transcript levels were calculated with the 2-ΔΔCt method using
GAPDH as the reference gene, and single-product amplification was verified by
examination of the PCR product melt curves.

2.5 Immunoblot analysis.
In order to determine levels of intracellular proteins, immunoblot analysis was performed
on cytoplasmic extracts as follows. Cells were seeded in 12-well plates at a density of
1 × 106 cells/well, treated with the ROCK inhibitor as indicated above, and then
incubated for 0, 15, 30, or 45 min with or without 10 ng/mL rhTNF-α. The cells were
then washed with cold PBS and scraped from culture plates using plastic cell scrapers in
the presence of 100 µL/well of lysis buffer containing 10 mM Tris-HCl, 5 mM disodium
EDTA,
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mM

potassium

chloride,

0.4%

IGEPAL

CA-630,

20

mM

4-nitrophenylphosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl
fluoride, 40 mM β-glycerophosphate, 20 mM sodium fluoride, and 1.44 µL/mL of
Protease Inhibitor Cocktail Set III (100 mM AEBSF, 80 µM aprotinin, 5 mM bestatin,
1.5 mM E-64, 2 mM leupeptin, and 1 mM pepstatin A; Calbiochem, San Diego, CA).
The cell/buffer suspensions were then transferred to microcentrifuge tubes and incubated
on ice for 10 min to allow for cell lysis. The resulting lysates were centrifuged at 12,000
rpm for 10 minutes at 4 °C to remove nuclei and any debris. Protein concentrations of
the lysates were determined with the Bio-Rad DC protein assay kit.
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Protein samples were diluted to equal concentrations with lysis buffer as needed,
and then three parts of the resulting protein dilutions were mixed with one part Laemmli
buffer containing 8% sodium dodecyl sulfate, 40% glycerol, 0.08% bromphenol blue, and
10% β-mercaptoethanol in 0.4 mM Tris-HCl buffer (6.8 pH). These mixtures were
heated to 95 °C for 5 min, and separated by SDS-PAGE on 10% polyacrylamide gels
with 4% stacking gels.

Proteins were then transferred to polyvinylidene difluoride

membranes with the BioRad Mini Trans-blot system. Transfers were run at 100 V for
1 h with ice cooling. For blocking, the membranes were incubated in 5% fraction V
bovine serum albumin (BSA; Fisher Scientific, Fair Lawn, NJ) in Tris-buffered saline
with 0.1% Tween-20 (TBST) for 2 h at room temperature. To probe for specific proteins,
the membranes were incubated with primary antibody in 5% BSA/TBST overnight at
4 °C with constant rocking. The membranes were then washed 3 times with TBST for
5 min per wash and incubated at room temperature with the appropriate HRP-conjugated
secondary antibody in 2.5% BSA/TBST for 2 h. The blots were then washed another
3 times with TBST before protein bands were detected using either LumiGLO Reagent
(Cell Signaling Technologies) or SuperSignal West Pico Chemiluminescent Substrate
(Thermo Scientific) detection systems. Images were captured by exposure on x-ray film.
For reprobing, membranes were washed twice in TBST, incubated at 50 °C for 12 min in
stripping buffer containing 2% SDS, 100 mM 2-mercaptoethanol, and 62.5 mM
Tris-HCl, and washed an additional 3 times in TBST before being reprocessed starting at
the blocking step described above. Densitometry was performed by scanning films and
analyzing images using the BioRad Quantity One software.
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2.6 Determination of CXCL8 levels in culture supernatants.
Caco-2 cells cultured in 24-well plates (2 × 105 cells/well) were treated with the ROCK
inhibitor for 2 h as previously described and incubated for 24 h in the presence of rhTNFα (10 ng/mL) or rhIL-1β (1 ng/mL). Culture supernatants were then collected and
analyzed for CXCL8 content using a DuoSet ELISA kit (R&D Systems) according to the
manufacturer’s protocol. Immediately after supernatant collection, trypsin/EDTA was
added to each well, and the number of cells per well was determined by direct count
using a hemacytometer. Color development in the ELISA plates was quantified using a
Bio-Tek EL312e microplate reader (Bio-Tek Instruments Inc., Winooski, VT), and the
resulting CXCL8 concentration values were normalized to 105 cells/well. An analysis of
cell counts showed that the ROCK inhibitor had no effect on cell viability (p = 0.98, data
not shown).

2.7 Statistics.
All experiments were run in three or more replicates (n ≥ 3), and the statistical
significance of any observed differences in treatment effects was determined using
ANOVA with Fisher’s protected least significant difference post-hoc test. Differences
with p < 0.05 are reported as significant.
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3. Results
3.1 The effect of inhibiting ROCK on TNF-α- and IL-1β-induced CXCL8 secretion in
Caco-2 cells
TNF-α and IL-1β are cytokines that are secreted by many cells types and play
major roles in inflammation. Not surprisingly, both of these cytokines have been found
at elevated levels in the intestinal tissues of IBD patients, suggesting that both may be
important in the development and progression of this disease [117, 120, 125, 132]. In
addition to TNF-α and IL-1β, several other inflammatory mediators have also been found
at elevated levels in IBD, including several chemokines, and in particular, CXCL8 [74,
144]. CXCL8 is known to be secreted by IEC [49] and is a major chemoattractant for
neutrophils, which further the progression of inflammation and produce substances
responsible for tissue damage in prolonged inflammation [45]. Previous experiments in
our laboratory have indicated that the signaling kinase, ROCK, plays a role in the
regulation of CXCL8 and other chemokine secretion in IEC cell lines stimulated with
IL-1β [176]. Because TNF-α is likewise elevated in IBD and is a major target in IBD
treatment, we asked whether the regulatory mechanism of TNF-α-induced CXCL8
secretion may also involve ROCK.
In a previous study, the effect of Y-27632, an inhibitor that has a high specificity
for ROCK [210-212], on IL-1β-induced CXCL8 secretion was examined by treating
Caco-2 cells with inhibitor concentrations ranging from 1 µM to 100 µM at 10-fold
intervals [176].

As would be expected, the strongest suppression of IL-1β-induced

CXCL8 secretion occurred at an inhibitor concentration of 100 µM, while the next
highest concentration (10 µM) did not produce a significant suppression at all. Although
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Y-27632 concentrations of 100 µM or more have been used in many studies [211, 213216], we reduced the dose to 40 µM in these current experiments in order to avoid any
potential off-target inhibitions that can occur at higher doses [211, 212]. In order to
confirm that a lower dose would still produce a significant suppression of IL-1β-induced
CXCL8 secretion, the previous experiments were repeated using 40 µM Y-27632. As
shown in Figure 2.1B, when the Caco-2 cells were treated with the 40 µM dose of the
ROCK inhibitor along with IL-1β, there was a significant 69% decrease in CXCL8
production compared to cells treated with IL-1β alone (p < 0.01). Furthermore, the lower
dose of ROCK inhibitor produced the same decrease (reported as 70%) observed with the
100 µM concentration in the previous experiments [176]. This strongly suggests that the
observed effect of the ROCK inhibitor is due to the direct suppression of ROCK activity
and is not a side effect of an off-target inhibition that would likely not be observed at the
lower dose. Additionally, the results of later dose-response experiments (Chapter 3,
Figure 3-5) showed that, while 10 µM ROCK inhibitor had a significant effect in
TNF-α-treated Caco-2 cells, the peak of the dose-dependent response occurred near
40 µM, providing further support for the use of the 40 µM concentration.
We next investigated the role of ROCK in TNF-α-stimulated CXCL8 secretion.
Caco-2 cells were seeded in FN-coated wells and incubated for 1 h to allow for
attachment, followed by treatment with 40 µM Y-27632. After an additional 2 h, the
cells were treated with or without TNF-α and incubated for 24 h. Analysis of the
resulting culture supernatants showed that levels of CXCL8 secreted by the Caco-2 cells
treated with the ROCK inhibitor were similar to levels secreted by untreated cells.
However, cells treated with TNF-α in addition to the ROCK inhibitor produced a
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significant 46% less CXCL8 (p < 0.05) than cells treated with TNF-α alone
(Figure 2.1A).

This observed reduction of CXCL8 secretion with ROCK inhibitor

treatment suggests that ROCK may play an important role in regulating TNF-αstimulated CXCL8 production in these cells.

3.2 CXCL8 mRNA levels were also suppressed by the ROCK inhibitor in TNF-α- and
IL-1β-treated Caco-2 cells
To determine if the ROCK inhibitor was suppressing CXCL8 secretion by
regulating mRNA levels, Caco-2 cells were again plated in FN-coated wells and treated
with or without the ROCK inhibitor and TNF-α as previously described. After a 6 h
incubation, total RNA was isolated from the cells, and relative CXCL8 transcript levels
were determined by real-time RT-PCR. Similar to its effect on secretion, the ROCK
inhibitor also had a significant suppressive effect on TNF-α-induced CXCL8 mRNA
levels, reducing it by 82% from levels in cells treated with TNF-α alone (Figure 2.2A).
Additionally, as with IL-1β-induced CXCL8 secretion, previous experiments in our
laboratory used a concentration of 100 µM of ROCK inhibitor to examine its effect on
mRNA levels in IL-1β-treated Caco-2 cells. Thus, the efficacy of using 40 µM ROCK
inhibitor was again tested. CXCL8 transcript levels in Caco-2 cells treated with both
40 µM ROCK inhibitor and IL-1β were significantly decreased by 57% compared to cells
treated with IL-1β alone, confirming that the 40 µM dose is sufficiently effective.
Furthermore, in both experiments, the ROCK inhibitor alone had no significant effect on
basal levels of CXCL8 mRNA.
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3.3 TNF-α-induced phosphorylation of p38 MAPK was unaffected by the ROCK
inhibitor.
The activation of p38 MAPK has been shown to be an important regulation event
in CXCL8 secretion in some cell types. In particular, Zu et al. [217] found that p38
MAPK activation is necessary for TNF-α-induced CXCL8 secretion in isolated human
neutrophils, while Maresca et al. [218] demonstrated a similar role for p38 MAPK in
mycotoxin-induced CXCL8 secretion in Caco-2 cells. Additionally, a study by Nwariaku
et al. [207] showed that the blockade of ROCK with Y-27632 abrogates p38 MAPK
kinase activity in human lung microvascular endothelial cells. To investigate if ROCK
may affect the activation of p38 MAPK in our system, we next examined the effect of
ROCK inhibitor on p38 MAPK phosphorylation in TNF-α-stimulated cells.

Again,

Caco-2 cells were plated and pre-treated with the ROCK inhibitor as described in the
Materials and Methods. After the addition of TNF-α, the cells were incubated for 0, 15,
30, and 45 min and then lysed. To determine levels of p38 MAPK phosphorylation, the
resulting cytoplasmic extracts were analyzed by Western blot (Figure 2.3). After 15 min,
there was a significant 9-fold increase in p38 MAPK phosphorylation in cells treated with
TNF-α alone (p < 0.01), which was sustained at similar levels through 45 min of the
experiment. In contrast to the previous results, however, the ROCK inhibitor had little to
no effect on the phosphorylation of p38 MAPK at any time point, indicating that
inhibiting ROCK does not affect the activation of this kinase in Caco-2 cells.
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3.4 Inhibiting ROCK had little to no effect on IκBα phosphorylation and degradation.
The NF-κB pathway plays a major role in inflammatory signal transduction. An
important event in the activation of this pathway is the phosphorylation and subsequent
proteasomal degradation of IκBα, which normally binds to NF-κB and prevents its
translocation to the nucleus. To determine whether the NF-κB pathway played a role in
the observed effect of the ROCK inhibitor on CXCL8 secretion in Caco-2 cells, Western
blot was utilized to examine both the phosphorylation and the degradation of IκBα. As
shown in Figure 2.4A, in cells stimulated with TNF-α alone, the level of IκBα
phosphorylation greatly increased by the 15 min mark, resulting in a 16-fold increase in
the ratio of phosphorylated to total IκBα compared to that of the unstimulated controls
(Figure 2.4B). As expected, this finding was matched by an apparent reduction in the
overall IκBα levels in those same cells (Figure 2.4C). However, this reduction was not
statistically significant. In cells treated with the ROCK inhibitor prior to TNF-α addition,
a similar increase in IκBα phosphorylation and decrease in total IκBα occurred, neither of
which were significantly different from the patterns seen with TNF-α alone. While this
evidence suggests that the NF-κB pathway is being activated by TNF-α, the inability of
ROCK inhibition to suppress IκBα phosphorylation and its subsequent degradation
suggests that ROCK does not participate in NF-κB activation under the conditions of
these experiments.

3.5 The effect of inhibiting ROCK on JNK activation in TNF-α-treated Caco-2 cells.
TNF-α and IL-1β are both known to activate JNK, an important regulator of
inflammation-related genes. JNK is expressed as p46 and p54 isoforms, each having
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different substrate specificities, and acts mainly by phosphorylating of members of the
Jun family of proteins [164]. Classically, Jun proteins are known to form dimers with
Fos proteins, which, together, make up the AP-1 transcription factor [166, 192]. Because
the CXCL8 promoter contains an AP-1 binding site [107], we next turned our attention to
the effect of inhibiting ROCK on TNF-α-induced JNK activation.

As shown in

Figure 2.5, treating the Caco-2 cells with TNF-α had no effect on the levels of
phosphorylated p46 JNK over the course of the 45 min time period, with or without the
ROCK inhibitor. This suggests that TNF-α does not activate p46 JNK in Caco-2 cells.
However, there was a significant 4.7-fold induction of p54 JNK phosphorylation by
15 min after the addition of TNF-α.

Furthermore, this TNF-α-induced elevation in

p54 JNK phosphorylation was reduced 50% by treatment with the ROCK inhibitor. This
reduction of TNF-α-induced activation of p54 JNK suggests a mechanism by which the
ROCK inhibitor suppresses CXCL8 secretion in TNF-α-stimulated Caco-2 cells.
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Figure 2.1: The Y-27632 ROCK inhibitor suppresses CXCL8 secretion in Caco-2
cells treated with either TNF-α or IL-1β. Caco-2 cells suspended in FBS-DMEM were
plated in FN-coated 24-well culture plates and allowed to attach for 1 h at 37 °C. The
medium was then removed and replaced with ITS-DMEM with or without 40 µM
Y-27632 ROCK inhibitor (RI). The cells were then incubated for 2 h before the addition
of either (A) TNF-α to a final concentration of 10 ng/mL or (B) IL-1β to a final
concentration of 1 ng/mL. After an additional 24 h incubation period, culture
supernatants were collected, and the cells in each well were counted. Supernatants were
analyzed for secreted CXCL8 by ELISA, and the resulting concentrations were
normalized to cell counts. Bars represent averages of 3 replicates ± 1 SEM (* p < 0.05,
** p < 0.01, *** p < 0.0001).
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Figure 2.2: The effect of inhibiting ROCK on TNF-α- and IL-1β-induced increases
in CXCL8 mRNA expression in Caco-2 cells. Caco-2 cells were seeded in FN-coated
6-well culture plates (1 × 106 cells/well) and pre-treated with ROCK inhibitor as
described in the Materials and Methods. Cells were then treated with (A) TNF-α
(10 ng/mL) or (B) IL-1β (1 ng/mL) and allowed to incubate for 6 h. Total RNA was then
extracted from the cells and analyzed using reverse transcription real-time PCR. CXCL8
transcript levels were normalized to GAPDH transcript levels and expressed as a value
relative to unstimulated controls. Means ± 1 SEM of (A) 3 and (B) 4 independent
experiments are shown. (** p < 0.01, *** p < 0.0001).
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Figure 2.3: TNF-α-induced phosphorylation of p38 MAPK in Caco-2 cells is not
affected by the ROCK inhibitor. Cells were seeded in FN-coated plates and pre-treated
with 40 µM ROCK inhibitor prior to the addition of TNF-α (10 ng/mL) as previously
described. The cells were then incubated for the indicated times and lysed. Cytoplasmic
fractions were separated by SDS-PAGE and analyzed by Western blot. A representative
blot is shown (A) with results of the band densitometry from four independent
experiments (B). Bars represent the means of the ratios (± 1 SEM) of phosphorylated
p38 MAPK band density to total p38 MAPK band density. (** p < 0.01)
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Figure 2.4: Inhibiting ROCK has little or no effect on IκBα phosphorylation and
degradation in TNF-α-stimulated Caco-2 cells. Cells were cultured with 40 µM
ROCK inhibitor and 10 ng/mL TNF-α and samples collected as described in Figure 2.3.
The levels of phosphorylated IκBα, total IκBα, and total β-actin were examined by
Western blot. A representative blot is presented here (A). Graphs show the means ±
1 SEM of phosphorylated IκBα band densities normalized to total IκBα (B) and of total
IκBα band densities normalized to total β-actin (C) from three separate experiments.
TNF-α elicited a significant response in IκBα phosphorylation (* p < 0.01). However, no
statistically significant differences were found between cells pre-treated with ROCK
inhibitor and those not pre-treated.
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Figure 2.5: The effect of inhibiting ROCK on JNK phosphorylation in Caco-2 cells
treated with TNF-α. Caco-2 cells were seeded in 12-well plates, pre-treated with 40 µM
ROCK inhibitor, and incubated with 10ng/mL TNF-α for the specified times as in
Figure 2.3. Cytoplasmic levels of phosphorylated JNK and total JNK were determined
by Western blot. (A) A representative blot is shown with open arrowheads pointing to
bands of the p54 JNK isoform and closed arrowheads to the p46 JNK isoform. The ratios
of phosphorylated JNK band densities to total JNK were calculated for each isoform
separately, and the means (± 1 SEM) of these ratios from three independent experiments
are shown for both p46-JNK (B) and p54-JNK (C). Significant differences between the
indicated treatment groups are marked with asterisks (* p < 0.05).
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4. Discussion
TNF-α plays a central role in IBD and is the target of the most current treatments
for this disease [177]. Despite the advanced nature of these treatments, there are still
risks of potentially serious side-effects, such as the activation of latent infections,
particularly tuberculosis [177]. Expanding our knowledge of how TNF-α and other proinflammatory cytokines, such as IL-1β, promote inflammation in the intestinal mucosa is
essential if new therapies are to be developed. As important components of the intestinal
mucosa, IEC can produce several immunoregulatory signaling molecules, including
CXCL8 [49-51, 114, 219], a major chemoattractant and activator of neutrophils.
Elevated levels of CXCL8 are found in IBD and may play an important role in the
pathogenesis of this disease [143]. Therefore, examining the regulatory mechanisms of
cytokine-stimulated CXCL8 production may provide key clues in the search for new
treatments.
In this study, we present evidence for the involvement of the Rho-associated
coiled-coil containing kinase, ROCK, in the regulation of the CXCL8 response in IEC.
Firstly, we found that inhibiting ROCK in intestinal epithelial Caco-2 cells resulted in a
marked decrease in TNF-α-induced CXCL8 secretion, which corresponded to a similar
decrease in CXCL8 mRNA levels. Further investigation of the role of ROCK in TNF-α
signal transduction in these cells showed that the ROCK inhibitor suppressed the TNF-αstimulated phosphorylation of the p54 isoform of JNK, while having no effect on the
TNF-α-induced activation of p38 MAPK or IκBα phosphorylation and degradation. We
also confirmed a prior result showing the effect of 40 µM ROCK inhibitor on IL-1βinduced CXCL8 mRNA expression using real-time RT-PCR, which was previously
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determined by semi-quantitative RT-PCR and agarose gel electrophoresis [176].
Additionally, the efficacy of a reduced dose of 40 µM ROCK inhibitor in suppressing
IL-1β-stimulated CXCL8 secretion was verified, an effect that was previously observed
at 100 µM ROCK inhibitor [176, 220, 221].
The CXCL8 promoter contains binding sites for both NF-κB and AP-1 [107,
222], and several studies have shown that these transcription factors, alone or together,
can activate CXCL8 mRNA transcription [197]. Additionally, Rho/ROCK signaling has
been found to mediate the activation of both of these transcription factors under various
conditions [123, 173, 175, 209, 223, 224]. Here we report that inhibiting ROCK resulted
in a corresponding reduction in TNF-α-induced JNK phosphorylation in Caco-2 cells,
while IκBα phosphorylation and degradation was not affected by ROCK inhibition.
Because inhibiting ROCK also led to a significant reduction in TNF-α-stimulated CXCL8
mRNA expression and protein secretion, these results suggest that, under these
conditions, the action of ROCK in CXCL8 production is probably mediated through
AP-1 and not NF-κB. This is in accord with previous results in our laboratory that
showed that inhibiting ROCK in IEC cell lines treated with IL-1β resulted in a similar
suppression of JNK activation, while having no effect on IKK kinase activity, IKK
phosphorylation, or IκBα phosphorylation and degradation [176, 220, 221]. Further
evidence for the role of ROCK in JNK activation and CXCL8 production comes from a
study by Shimada and Rajagopalan [209] in which inhibiting ROCK in LPA-treated
HUVECs abrogated phosphorylation of both JNK and c-Jun in addition to suppressing
LPA-induced CXCL8 mRNA expression and secretion.

Furthermore, that study

established that NF-κB activation in LPA-stimulated HUVECs was also ROCK-
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dependent, although in this case, CXCL8 production was shown to be regulated
independently of NF-κB. Segain et al. [123] also demonstrated that ROCK could play a
role in the activation of the NF-κB pathway. In that study, ROCK inhibition was shown
to block TNF-α-induced IκBα degradation and NF-κB nuclear localization in peripheral
blood mononuclear cells isolated from patients with CD. Inhibiting ROCK also reduced
IKKα activation and IκBα degradation in the monocytic THP-1 cell line stimulated with
IL-1β.

While much is still unknown, it appears that ROCK may be an important

regulator of AP-1-driven responses and sometimes NF-κB-driven responses, although
which pathway is affected by ROCK seems highly dependent upon the conditions and
cell type.
The p38 MAPK has also been shown to regulate CXCL8 production, both at the
transcriptional and post-transcriptional level [203, 204]. Here we show that TNF-α
induced a 9-fold increase in p38 MAPK phosphorylation. This effect was unchanged by
pre-treating the cells with ROCK inhibitor, suggesting that p38 MAPK does not play a
part in the ROCK-dependent regulation of CXCL8. In addition to transcriptional control,
p38 MAPK can also phosphorylate ARE-binding proteins and thus, has an effect on
mRNA stability mediated by these proteins [205].

However, in TNF-α-stimulated

Caco-2 cells, ROCK inhibition had no effect on CXCL8 mRNA stability (see Chapter 3),
supporting the assertion that p38 MAPK is not involved in ROCK-mediated CXCL8
production in these cells.
Until the recent report from our laboratory [176], ROCK had not been identified
as a possible mediator of JNK-mediated transcriptional control of CXCL8 responses in
IEC. In that report, ROCK inhibition was shown to significantly suppress the activation
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of both the p46 and p54 isoforms of JNK in IL-1β-treated Caco-2 cells and IEC-6 cells,
indicating that ROCK may be an important player in IL-1-to-JNK signaling.
Interestingly, TNF-α treatment had no effect on the phosphorylation of p46 JNK in
Caco-2 cells. However, phosphorylation of the p54 isoform was increased 4.7-fold by
TNF-α treatment.

This isoform-specific activation was significantly reduced by

pretreatment with the ROCK inhibitor, suggesting that ROCK also plays an important
part in TNF-α-to-JNK signaling for optimal CXCL8 secretion by IEC.
The implications of the preferential activation of p54 JNK in these cells are, as
yet, unclear. However, due to differences in substrate binding affinities among the JNK
isoforms, this may provide a mechanism that allows for the activation of a specific subset
of AP-1 proteins and/or other JNK-mediated responses. For instance, p54 JNK has been
shown to bind c-Jun with a 25-fold greater affinity than p46 JNK [225], so the activation
of the p54 isoform by TNF-α may be a way to selectively regulate transcription of genes
under the control of c-Jun-containing dimers, such as c-Jun/c-Fos. JNK is also known to
phosphorylate several other transcription factors, including Elk-1 and ATF2 [226], and
further experimentation is required to determine the particular JNK substrate(s) that may
be involved in the regulation of TNF-α-induced CXCL8 secretion in IEC. Because of the
transient nature of kinase-substrate binding, a full survey of a kinase's substrates can be
difficult.

Here, a phosphoproteomic approach may be best in which extracts from

TNF-α-stimulated cells treated with or without a JNK inhibitor would be enriched for
phosphoproteins using metal oxide affinity chromatography (MOAC) [227], followed by
mass spectrometry to identify substrate proteins.
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Also of interest is the difference in the profiles of JNK activation by IL-1β versus
TNF-α. While increased phosphorylation was limited to p54 JNK in TNF-α-treated
Caco-2 cells, our previous experiments showed that exposure to IL-1β resulted in
increased phosphorylation of both p46 and p54 JNK isoforms [176]. At first glance, this
might seem to imply that JNK-mediated responses induced by TNF-α may be a subset of
those induced by IL-1β, and this may be true. However, there are at least eight splice
variants of JNK1/2, four of which are approximately 54 kDa [164]. Thus, it is possible
that the observed increase in phosphorylation of p54 JNK in IEC may be a result of the
selective phosphorylation of specific p54 JNK variants or sets of variants, such that
TNF-α may activate an entirely different p54 variant than does IL-1β.

Such non-

redundant activation of JNK isoforms could explain some of the differences in IEC
responses to either of these cytokines as well as suggesting a potential mechanism for
IL-1β / TNF-α synergistic effects [95].
Another point to note is that ROCK inhibition did not result in complete
suppression of TNF-α-induced CXCL8 secretion or mRNA expression. This is not
surprising considering that TNF-α activates both NF-κB and AP-1 pathways
simultaneously, which are both known to regulate CXCL8 transcription [107, 187, 228].
The suppression of JNK signaling by the ROCK inhibitor probably accounts for the
observed 46% reduction in CXCL8 secretion and 82% reduction in CXCL8 mRNA,
while the inability of the ROCK inhibitor treatment to affect IκBα phosphorylation and
degradation in our experiments suggests that the remaining uninhibited CXCL8
production might be mediated by NF-κB. It is also possible that the residual CXCL8
levels are induced or enhanced through the action of p38 MAPK, which we also found to
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be activated by TNF-α independently of ROCK. In fact, CXCL8 secretion and mRNA
expression in LPA-stimulated HUVECs have been shown to be dependent on p38 MAPK
but completely independent of NF-κB [209]. Furthermore, inhibiting p38 MAPK in
LPA-treated HUVECs resulted in only a partial reduction in CXCL8 production, and,
interestingly, complete suppression of CXCL8 required the concurrent inhibition of both
p38 MAPK and JNK. A similar multiple-pathway regulatory mechanism is likely at play
in Caco-2 cells as well, although it is unclear which combination of pathways is
responsible for the observed TNF-α-induced CXCL8 expression. Similar to what was
found in LPA-stimulated HUVECs [209], it may be the case in Caco-2 cells that CXCL8
production is under control of p38 MAPK and JNK with p38 MAPK being responsible
for the observed residual CXCL8 expression when JNK activation is suppressed by the
ROCK inhibitor. Alternatively, the residual CXCL8 expression may be due to NF-κB,
since this pathway was not affected by the ROCK inhibitor, which suggests that a
combination of NF-κB and JNK are required for the full expression of CXCL8 in TNF-αstimulated Caco-2 cells. Furthermore, it is also possible that all three pathways, JNK,
NF-κB, and p38 MAPK act together or in concert with some as yet unidentified pathway
to induce CXCL8.
ROCK is an important regulator of cell movement and cytoskeletal rearrangement
[172, 229, 230]. Because cell movement is essential for the wound healing process, it is
likely that the edges of gastrointestinal ulcerations, which are commonly seen in IBD,
may be areas of high ROCK activity. Furthermore, our results suggest that ROCK could
also play a role in the cytokine responses of IEC, particularly those at the edges of
ulcerations.
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In our experiments, the Caco-2 cells were treated with TNF-α three hours after
plating and were sub-confluent throughout the entire duration. During this period, the
cells attached, spread, and began migrating toward one another, processes that require the
formation and turnover of focal adhesions and stress fibers and that are also known to
involve both ROCK and integrins [172]. Similarly, during healing, IEC at the wound
edge also spread and migrate towards one another in a Rho/ROCK dependent manner
[101, 231-233]. When considered along with these facts, the results of our experiments
could suggest that ROCK may have the additional role of enhancing the TNF-α- and
IL-1β-stimulated CXCL8 responses in wound-edge IEC. In this scenario, the subsequent
increase in CXCL8 near the wound edge would direct neutrophils to the wound opening
where they could combat any invading microbes. The possibility of such a multifaceted
role suggests that ROCK may be an important and essential player in the overall response
of IEC during intestinal wounding and inflammation.
Despite the incomplete suppression of CXCL8 secretion observed in Caco-2 cells, ROCK
inhibition may still be an attractive treatment option for IBD.

Reduced CXCL8

production by IEC, particular at the wound edge, would likely mean fewer neutrophils
infiltrating inflamed and ulcerated intestinal tissues.

The resultant decrease in pro-

inflammatory cytokines, as well as tissue-damaging substances, that are produced by
neutrophils could shift the balance of immune regulatory signals toward antiinflammatory and healing responses. While ROCK inhibition in IEC could be effective
treatment in and of itself, a study by Segain et al. [123] has shown that the ROCK
inhibitor can also significantly suppress the secretion of TNF-α by lamina propria
mononuclear cells isolated from patients with CD and rats with TNBS-induced colitis.
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This finding corresponded with a significantly reduction in inflammation in the intestinal
tissues of rats with TNBS colitis when the ROCK inhibitor was administered. In that
study, however, the role of IEC was not considered, and the observed reduction in
inflammation may have resulted, at least in part, from the blockade of ROCK-mediated
responses in IEC. Taken together, these results indicate that the ROCK inhibitor could be
a potent anti-inflammatory agent that reduces pro-inflammatory activity in multiple cell
types and that ROCK inhibition could be a highly effective treatment strategy for IBD.
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Chapter 3
The Role of ROCK in the Differential Regulation of Cytokine-Induced
Production of CXCL8 Compared to CCL2 and CCL20
in Intestinal Epithelial Cells
1. Introduction
Chemokines are a group of cytokines, consisting of small, soluble, secreted
proteins that act as chemoattractants and activators of leukocytes [100]. Chemokines are
organized into four subfamilies, C, CC, CXC, and CX3C, based on the arrangement of
conserved cysteine residues with almost all chemokines falling into either of the two
major subfamilies: CXC or CC [98, 234].

Neutrophils respond mainly to CXC

chemokines, in particular CXCL8, although they are also acted upon by CXCL1 and
CXCL2 [100, 101, 108]. In contrast, monocytes and macrophages are mainly, but not
exclusively, responsive to CC family chemokines such as CCL2 [100, 101]. The modes
of action upon other leukocytes are not as well delineated between the CXC and CC
subfamilies. For instance, CXCL10 exerts its effects on TH1 lymphocytes and natural
killer cells [98, 100], whereas CCL20 is known to act upon mucosal-homing
T lymphocytes and immature dendritic cells [101, 113].
Inflammatory Bowel Disease (IBD) is characterized by the aberrant expression of
many immunomodulatory molecules, including IL-1β, TNF-α, IL-6 [235], as well as
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many chemokines, such as CXCL1, CXCL8, CCL2, and CCL20 [141]. CXCL8 is found
at especially high levels in IBD compared to many other chemokines [74, 141], and
accordingly, high numbers of neutrophils are also found in IBD-affected tissues [143].
IEC form a major component of the mucosal immune system, and thus, IEC isolated from
IBD patients have been found to produce many of these aberrantly expressed chemokines
at elevated levels [46, 74, 124, 144, 184]. Furthermore, IEC cell lines stimulated with
either IL-1β or TNF-α have also been shown to produce many of these same chemokines
[46, 50, 51]. Because IEC have the ability to produce chemokines and because the IEC
microenvironment in IBD tissues contains the known inducers of chemokine production,
IL-1β and TNF-α [78, 117, 119-121, 124, 125], it is likely that IEC make a considerable
contribution to the increased levels of chemokines found in IBD.
The TNF-α signal is transduced through a highly complex network of intracellular
signaling pathways. One of the main modes of action of TNF-α signaling is the initiation
of transcription of immediate early genes through the activation of the NF-κB and AP-1
transcription factors [87, 187]. One such immediate early gene is the chemokine CXCL8,
which can be activated by NF-κB alone or in combination with AP-1 in a synergistic
manner [106, 107, 197]. The CC chemokine, CCL2, is another gene whose transcription
and secretion can be induced by TNF-α [112]. Similar to CXCL8, CCL2 transcription is
also regulated by NF-κB and AP-1 as well as by other transcription factors [112, 197].
Aside from NF-κB and AP-1, TNF-α is known to activate several other signaling
pathways. These include the p38 MAPK pathway, which is known to affect chemokine
production by regulating AU-rich element (ARE)-binding proteins and subsequently
increasing mRNA stability [87, 187, 205]. In addition, TNF-α has also been found to
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activate the PI3K/Akt pathway, the ERK pathway, and the protein kinase C (PKC)
pathway [86, 154, 187, 236].
In addition, signaling through ROCK has also been found to be activated by
TNF-α stimulation, and recently, evidence for a role for ROCK in TNF-α-associated
inflammation has been growing. Segain et al. [123] found that inhibiting ROCK reduced
the levels of inflammation in the colons of rats with TNBS-induced colitis. Furthermore,
they found that ROCK inhibition blocked the TNF-α-induced degradation of IκBα in
peripheral blood mononuclear cells and also blocked TNF-α-induced nuclear localization
of NF-κB as shown by immunofluorescence. In experiments in our laboratory, inhibiting
ROCK significantly reduced TNF-α-stimulated mRNA expression and secretion of
CXCL8 in IEC cell lines and also suppressed the TNF-α-induced activation of MKK4
and p54 JNK [237, Chapter 2]. Classically, ROCK has been implicated in the regulation
of processes involving integrins and the cytoskeleton, such as cell adhesion, stress fiber
formation, actin-myosin contractility, and integrin signaling [170, 172, 238, 239].
Because ROCK is known to play roles in both integrin and TNF-α signaling, it may be
possible that ROCK could act as a convergence point for crosstalk between of integrin
and TNF-α signals.
In addition to showing that ROCK is involved in the TNF-α-induced production
of CXCL8 in Caco-2 and DLD-1 cells, studies from our lab have also indicated that
ROCK is involved in the IL-1β-stimulated production of CXCL8 in Caco-2 cells and in
the IL-1β-stimulated production of CCL2 in rat-derived IEC-6 cells [176, 237,
Chapter 2]. These results suggest that ROCK may play a role in the regulation of
chemokine responses by IEC, and thus may be a potential therapeutic target for the
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treatment of IBD. Therefore, to further elucidate the role of ROCK in IEC chemokine
responses, we extended our investigations by examining the function of ROCK in
cytokine-induced CCL2 production in the human-derived Caco-2 cell line and also in the
cytokine-induced production of CCL20, another IBD-associated CC chemokine.
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2. Materials and Methods
2.1 Inhibitors.
Wortmannin, a specific inhibitor of PI3K and triciribine, a specific inhibitor of
Akt/protein kinase B were purchased from Sigma-Aldrich (St. Louis, MO). GF109203X,
a specific inhibitor of conventional protein PKC isoforms (α, β, γ, δ, and ε subtypes [240,
241]) was obtained from Enzo Life Sciences (Farmingdale, NY) as was the transcription
inhibitor, actinomycin D, and the ROCK inhibitor, Y-27632.

PD98059, a specific

inhibitor of MEK1/2, was obtained from EMD Biosciences (Billerica, MA).

2.2 Cell culture conditions.
The human colonic epithelial Caco-2 cell line (ATCC) was cultured in FBS-DMEM and
maintained at 37°C in a humidified 10% CO2 atmosphere as described in Chapter 2. For
experiments, Caco-2 cells were seeded in FN-coated 6-, 12-, and 24-well plates as
described in Chapter 2. The cells were allowed to attach for 1 h at 37°C, and then the
medium was aspirated and replaced with serum-free ITS-DMEM or ITS-DMEM
containing 40 µM Y-27632 ROCK inhibitor. After an additional 2 h of incubation, the
cells were treated with 10 ng/mL rhTNF-α (R&D Systems, Minneapolis, MN) and
incubated for the appropriate time periods required by each experimental protocol. In
some experiments, additional chemical inhibitors were added prior to treatment with
TNF-α as indicated in the following sections.
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2.3 Determination of chemokine levels in culture supernatants.
Caco-2 cells were seeded in FN-coated 24-well plates (2 × 105 cells/well) and treated
with Y-27632 as described above. After pretreatment with the ROCK inhibitor for 2 h,
either 10 ng/mL TNF-α or 1 ng/mL IL-1β was added to the wells, and the plates were
incubated for 24 h. Culture supernatants were analyzed for chemokine content using
CXCL8, CCL2, or CCL20 DuoSet ELISA kits (R&D Systems), and the number of cells
in each well was determined as described in Chapter 2.

Chemokine levels were

normalized to cell counts and expressed in pg/105 cells.
In experiments investigating which signaling pathways might be involved in
ROCK-mediated regulation of chemokine secretion, the cells were also pretreated with
the inhibitors listed in Table 3-1, either separately or in combination with the ROCK
inhibitor. For Wortmannin, the inhibitor or vehicle alone was added to each well after
the cells had been incubated for 1 h in the presence of the ROCK inhibitor. This was
followed by an additional 1 h incubation period before treatment with TNF-α, such that
the total time of pretreatment with ROCK inhibitor was 2 h, maintaining consistency with
previous experiments. For the remaining inhibitors, the cells were pretreated with ROCK
inhibitor for 1.5 hr before the addition of the second inhibitor. The cells were then
incubated for an additional 0.5 h, again for a total of 2 h of treatment with the ROCK
inhibitor prior to treatment with TNF-α. After the addition of TNF-α, the plates were
incubated for 24 h, and levels of secreted chemokines were determined as described
above.
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Table 3-1. Inhibitor treatments
Inhibitor

Time of treatment
prior to TNF-α
addition

Final
[inhibitor]

Vehicle
(% DMSO in
ITS-DMEM)

Final
% DMSO
in culture

Wortmannin

1h

10, 100 nM

0.4

0.005

Triciribine

30 min

1, 10 µM

2

0.05

PD98059

30 min

25 µM

5.4

0.13

GF109203X

30 min

2.5 µM

5.4

0.13

2.4 Quantification of relative mRNA levels.
The relative levels of CXCL8 and CCL2 mRNAs in total RNA isolated from TNF-αstimulated Caco-2 cells were determined using real-time RT-PCR as described in Chapter
2. To do so, the cells were first seeded in FN-coated 6-well culture plates at a density of
1 × 106 cells/well. The cells were then pretreated with ROCK inhibitor or medium alone
for 2 h before treatment with either 10 ng/mL TNF-α or 1 ng/mL IL-1β for 6 h. Total
RNA was isolated from the cells and converted to cDNA, which was then analyzed by
real-time PCR using CXCL8, CCL2, and GAPDH primer sets (SABiosciences, Valencia,
CA).

2.5 Examination of mRNA decay rates.
The decay rates of CXCL8 and CCL2 mRNAs were determined by measuring relative
transcript levels over a time course of 2 h. Caco-2 cells were pretreated with or without
the ROCK inhibitor and treated with TNF-α as described in the previous section. After
incubation for 6 h with TNF-α, the transcriptional inhibitor, actinomycin D, was added to
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all wells at a concentration of 10 μg/mL. The plates were returned to the incubator, and
total RNA was extracted from the cells after 0, 0.5, 1, and 2 h. Relative mRNA levels
were determined using real-time RT-PCR as previously described.

2.6 Immunoblot analysis of ERK phosphorylation.
Cytoplasmic extracts were prepared from Caco-2 cells treated with the ROCK inhibitor
and TNF-α as described in Chapter 2. The extracts were analyzed for phospho-ERK and
total ERK using Western blot (Chapter 2), and the levels of phospho-ERK were
determined by band densitometry and normalized to total ERK band densities.
Antibodies against phospho-ERK (p44/p42) and total ERK (p44/p42) were purchased
from Cell Signaling Technologies (Beverly, MA), as were the HRP-conjugated antimouse and anti-rabbit antibodies used for detection.

2.7 Statistics
Statistical significance was determined using ANOVA followed by Fisher's protected
least significant difference post-hoc test with the level of significance set at p < 0.05. A
minimum of three replicates (n ≥ 3) were run for each experiment.
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3. Results
3.1 The effect of inhibiting ROCK on chemokine secretion by IL-1β- and TNF-αstimulated Caco-2 cells
IEC taken from IBD patients and IEC cell lines treated with inflammatory stimuli
have both been shown to produce the chemokine CXCL8, a major neutrophil
chemoattractant and activator with increased expression in IBD [49, 74, 143].

In

previous reports, we have shown that ROCK is required for optimal secretion of CXCL8
in the Caco-2 human colonic epithelial cell line when stimulated with either IL-1β or
TNF-α [176, 237, Chapter 2], two important pro-inflammatory cytokines also found at
elevated levels in IBD [78, 132]. To further elucidate the role that ROCK might play in
IEC inflammatory responses, we began by expanding our investigations to include CCL2
and CCL20, two other important chemokines with elevated expression in IBD [74, 145,
146].
In order to determine if ROCK is involved in the regulation of CCL2 or CCL20
secretion in IEC, Caco-2 cells were added to the wells of FN-coated culture plates and
pretreated with the ROCK inhibitor, Y-27632, at a concentration of 40 µM as before
(Chapter 2). The cells were then stimulated with TNF-α (10 ng/mL) or IL-1β (1 ng/mL)
for 24 hours, and the resulting culture supernatants were tested by ELISA. We first
analyzed the supernatants for accumulated CXCL8 to confirm the reproducibility of our
prior results and to establish a baseline response for the sake of making more accurate
comparisons within this experiment set. As expected, CXCL8 secretion in Caco-2 cells
was greatly increased by the addition of either TNF-α (Figure 3.1A) or IL-1β
(Figure 3.2A) compared to untreated controls, while the cells pre-treated with the ROCK
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inhibitor yielded significantly reduced cytokine-stimulated CXCL8 secretion as
compared to cells treated with TNF-α alone.
Because CCL2 is also produced by IEC in response to pro-inflammatory signals
[51, 146], we hypothesized that inhibiting ROCK in Caco-2 cells would also result in a
suppression of CCL2 secretion similar to that of CXCL8. Furthermore, this hypothesis
followed from previous results in our laboratory that showed that inhibiting ROCK
suppressed IL-1β-stimulated CCL2 mRNA expression and secretion in rat-derived IEC-6
cells [176]. To the contrary of this hypothesis, Caco-2 cells pretreated with the ROCK
inhibitor yielded a significant 2-fold enhancement of TNF-α-induced CCL2 secretion
(Figure 3.1B) and a significant 1.5-fold enhancement of IL-1β-induced CCL2 secretion
(Figure 3.2B) as compared to levels in cells treated with TNF-α or IL-1β alone. This
result led us to ask if this effect was specific to CCL2 or whether it might extend to other
C-C chemokines.

To answer this, the culture supernatants were next analyzed for

CCL20, a chemokine that not only is expressed at abnormally high levels in IBD [114,
115] but also has been shown to be produced almost exclusively by IEC in inflamed
intestinal mucosae [114]. Similar to CCL2 secretion, there was a 2-fold increase in
TNF-α-induced CCL20 secretion (Figure 3.1C) and a 1.4-fold increase in IL-1β-induced
CCL20 secretion (Figure 3.2C) by Caco-2 cells treated with the ROCK inhibitor over
cells without the inhibitor. This suggests that the activation of ROCK somehow leads to
a suppression of IL-1β- and TNF-α-induced C-C chemokine responses by IEC.
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3.2 ROCK inhibition also results in the differential regulation of CCL2 and CXCL8 at
the mRNA level in Caco-2 cells treated with TNF-α or IL-1β
We have previously shown that ROCK-dependent CXCL8 production is regulated
at the mRNA level in Caco-2 cells treated with either IL-1β or TNF-α [176, Chapter 2].
Thus, we next set out to determine whether the opposing regulatory mechanism that
partially suppresses CCL2 and CCL20 secretion also affected mRNA levels using CCL2
as a representative from this group. To do this, Caco-2 cells were seeded in FN-coated
culture plates, treated with the ROCK inhibitor and TNF-α as specified above, and
analyzed by real-time RT-PCR.
Similar to our experiments examining chemokine secretion, the samples were first
analyzed for CXCL8 mRNA for comparison within this set of experiments. Consistent
with the results reported in Chapter 2, TNF-α treatment elicited a 30-fold up-regulation of
CXCL8 mRNA levels, which was significantly reduced with ROCK inhibition
(Figure 3.3A). A subsequent analysis of these samples showed that TNF-α induced a
significant 8-fold increase in CCL2 mRNA levels as compared to untreated controls,
which was boosted to nearly 14-fold over untreated controls when TNF-α and the ROCK
inhibitor were administered together (Figure 3.3B). The expression of CCL2 mRNA in
IL-1β-stimulated Caco-2 cells was likewise enhanced to approximately 15-fold over
untreated controls by the ROCK inhibitor versus an 8-fold increase in cells treated with
IL-1β alone (Figure 3.4). In both cases, whether TNF-α or IL-1β treatment, concomitant
ROCK inhibition resulted in the enhancement of CCL2 mRNA levels.
The finding that the ROCK inhibitor enhances CCL2 and CCL20 responses
directly contradicted our initial hypothesis that predicted a suppression similar to that
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seen for CXCL8. Because of the surprising nature of this finding, our next objective was
to confirm that the observed enhancement was not due to an off-target side-effect of the
ROCK inhibitor.

As discussed in Chapter 2, off-target effects can occur at higher

concentrations of the ROCK inhibitor, while at lower concentrations, the inhibitor is
highly specific for ROCK [211, 212]. The 40 µM dose used in these experiments was
chosen to maximize ROCK inhibition. However, somewhat lower doses can still produce
significant, although not maximal, inhibition of ROCK.

If the observed partial

suppression of CCL2 and CCL20 responses was in fact mediated by ROCK, then treating
cells with a reduced dose of 10 µM ROCK inhibitor would still result in a significant
enhancement, whereas if the effect was mediated by an off-target kinase with a higher
half-maximal inhibitory concentration (IC50), such as PKC, protein kinase A, or the citron
kinase [211], a dose of 10 µM should produce little or no enhancement.
To test this, CCL2 mRNA expression was examined in TNF-α-stimulated Caco-2
cells pretreated with concentrations of ROCK inhibitor ranging from 0 to 100 µM
(Figure 3.5). In accord with the hypothesis that the observed effect was indeed due to
ROCK-specific inhibition, the lowest dose (10 µM) of ROCK inhibitor produced a
significant enhancement of TNF-α-stimulated CCL2 mRNA expression. In fact, there
was no significant difference between the enhancement produced with 10 µM ROCK
inhibitor and that produced with the 40 µM concentration, which is strong evidence that
the enhancement effect was due to the specific inhibition of ROCK.

Interestingly,

increasing the dose of the ROCK inhibitor to 100 µM abolished the enhancement effect.
This return of CCL2 mRNA expression to TNF-α-only levels suggests that the activity of
off-target kinases may be involved in CCL2 expression.
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However, since the

enhancement effect remained undiminished up to the 40 µM dose of ROCK inhibitor, it
is likely that the activity of such kinases is largely or completely unaffected by the ROCK
inhibitor under the conditions used in this study.

3.3 The effect of inhibiting ROCK in TNF-α-treated Caco-2 cells on CXCL8 and CCL2
mRNA stability
Having established that inhibiting ROCK results in the enhancement of TNF-αinduced CCL2 responses in Caco-2 cells, we next set out to investigate how ROCK might
be effecting such disparate regulatory outcomes between CXCL8 and CCL2. Our data
showed that ROCK-dependent CXCL8 secretion and the ROCK-dependent attenuation of
CCL2 secretion were both associated with corresponding changes in steady-state mRNA
levels. Post-transcriptional control of steady-state mRNA levels through the p38 MAPK
mediated modulation of deadenylation-dependent mRNA decay has been identified as a
fundamental mechanism in the regulation of many cytokines, including several
chemokines [242]. Therefore, our first step in dissecting the differential regulation of
CXCL8 and CCL2 was to examine the effect of the ROCK inhibitor on mRNA
degradation. To do this, Caco-2 cells were incubated with the ROCK inhibitor and
TNF-α and then treated with actinomycin D to halt transcription. Measurements of
mRNA levels over the course of a subsequent 120 minute time period showed that
inhibiting ROCK had little or no effect on the decay rate of CCL2 mRNA or of CXCL8
mRNA (Figure 3.6). To note, the results do show an apparent, but slight, destabilization
of CCL2 mRNA at 120 minutes in cells treated with TNF-α and the ROCK inhibitor,
suggesting that inhibiting ROCK may lead to lower steady-state mRNA levels. This,
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however, is completely inconsistent with our previous observation that ROCK inhibition
resulted in higher steady-state CCL2 mRNA levels and is likely an anomalous reading,
especially considering the small sample size (n = 2).

3.4 Investigation of the PI3K/Akt pathway for involvement in the ROCK-dependent
attenuation of TNF-α-induced CCL2 secretion
Our previous results indicating that ROCK mediates JNK activation in Caco-2
cells stimulated with IL-1β or TNF-α [176, Chapter 2] support a straight-forward model
of regulation in which optimal CXCL8 transcription is contingent upon the ROCKdependent activation of JNK. At the same time, it appears that ROCK also governs a
negative regulatory mechanism that has a suppressive effect on CCL2 and CCL20
expression. In light of the divergent nature of these responses, we reasoned that the
suppression of CCL2 mRNA production is most likely independent of JNK, and,
therefore, set out to identify additional signaling pathways involved in ROCK-mediated
CCL2 expression. Both a study using HUVECs and a study using human retinal pigment
epithelial cells showed that activation of the PI3K/Akt pathway is essential for CCL2
secretion in cells treated with TNF-α [153, 154]. The study with human retinal pigment
epithelial cells also found that, unlike CCL2, the induction of CXCL8 secretion by
TNF-α occurred independently of PI3K/Akt activation [153]. Although this pattern of
regulation does not directly correspond to the ROCK-mediated regulation of CXCL8 and
CCL2 seen in Caco-2 cells, the fact that the effects of PI3K/Akt activation were limited
to CCL2 secretion in human retinal pigment epithelial cells prompted us to ask whether
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the PI3K/Akt pathway might be playing a similar role in the ROCK-dependent regulatory
mechanisms governing CCL2 secretion in Caco-2 cells.
We approached this query by first examining the effect of the specific PI3K
inhibitor, Wortmannin, on the enhancement of TNF-α-stimulated CCL2 secretion by the
ROCK inhibitor. As in previous experiments, Caco-2 cells were again pre-treated with
the ROCK inhibitor and then incubated in the presence of TNF-α. However, in this set of
experiments, the cells were also pre-treated with Wortmannin at 10 and 100 nM (or with
vehicle). In the vehicle-treated group, TNF-α once again elicited a significant increase in
CCL2 secretion, which was enhanced further by ROCK inhibition (Figure 3.7). This
pattern of response to TNF-α and the ROCK inhibitor was unchanged when the cells
were pre-treated with Wortmannin at either concentration.
While this is fairly strong evidence that PI3K/Akt signaling is not involved in
regulating CCL2 secretion in TNF-α-treated Caco-2 cells, there have been reports that
PI3K inhibition is not, in some cases, sufficient to abrogate the downstream activity of
Akt. Studies have identified other regulatory proteins, such as p38 MAPK and PTEN, as
possible PI3K-independent mediators of downstream Akt activity [243-248]. Therefore,
to confirm the results seen with Wortmannin, we next tested whether directly inhibiting
Akt using triciribine (Akt inhibitor V) would have an effect on CCL2 secretion in these
cells. Unlike inhibiting PI3K with Wortmannin, Akt inhibition resulted in an overall
reduction in TNF-α-induced CCL2 secretion, but only at the highest concentration of
triciribine, 10 µM (Figure 3.8). Despite this reduction, inhibiting Akt in ROCK inhibitortreated cells had no effect on the ROCK-dependent enhancement of TNF-α-induced
CCL2 secretion, resulting in an increase proportionally equivalent to that seen in cells
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treated without the Akt inhibitor (1.6-fold vs. 1.9-fold enhancement with or without the
Akt inhibitor respectively; p > 0.5).

3.5 The effects of PKC, MEK, and ROCK inhibition on CCL2 secretion in TNF-αtreated Caco-2 cells
Several studies have shown that PKC regulates the secretion of CCL2 and/or
CXCL8 under certain conditions [249-251]. In other cases, the secretion of either or both
of these chemokines is under the control of ERK or PKC and ERK together [252-257].
Among these studies are reports that point toward possible roles for PKC and ERK in
negative regulatory mechanisms governing cytokine secretion [251-253]. To determine
whether PKC or ERK might be involved in the regulation of chemokines in IEC, each
pathway was blocked separately with chemical inhibitors, and then the effects of these
inhibitors on the ROCK-mediated attenuation of TNF-α-stimulated CCL2 secretion were
examined. To block PKC signaling, Caco-2 cells were treated with GF109203X, a potent
inhibitor of the PKCα, PKCβ, PKCγ, PKCδ, and PKCε isoforms [240, 241], while the
ERK pathway was blocked using PD98059, which inhibits MEK1/2, the upstream
kinases that phosphorylate and activate ERK1/2 [168, 258].
In Caco-2 cells treated with the PKC inhibitor, there was a small, but not
significant, increase in TNF-α-elicited CCL2 secretion, which occurred independently of
ROCK inhibition (Figure 3.9A). However, this increase should be noted as a potential
sign that PKC may have a minor and/or generic role in IEC chemokine secretion. More
importantly, the blockade of PKC had little or no effect on the ability of ROCK to
suppress CCL2 secretion in TNF-α-treated Caco-2 cells, since the inhibition of ROCK
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still resulted in a significant enhancement of TNF-α-induced CCL2 secretion when PKC
was concurrently inhibited, indicating that PKC plays little or no role in CCL2 regulation.
In contrast, when MEK/ERK was inhibited, there was a significant 1.8-fold
increase in TNF-α-induced CCL2 secretion over levels from cells treated with TNF-α but
without the MEK/ERK inhibitor (Figure 3.9B). In addition, this increase in TNF-αstimulated CCL2 secretion was to a level equal to that of TNF-α-stimulated CCL2
secretion from cells treated with the ROCK inhibitor. Furthermore, the MEK/ERK
inhibitor had no effect on CCL2 secretion in cells treated with TNF-α and the ROCK
inhibitor. Taken together, these results suggest that the MEK/ERK pathway may play an
import role in the ROCK-associated control of CCL2 responses in Caco-2 cells.

3.6 Blocking PKC or MEK activity had no effect on the suppression of TNF-αstimulated CXCL8 secretion in Caco-2 cells
While these experiments provided insight into the mechanism responsible for the
partial suppression of CCL2 secretion, the question of whether MEK or PKC played any
role in mediating ROCK-potentiated CXCL8 secretion had yet to be answered. Analysis
of culture supernatants from the above experiments revealed that ROCK inhibition
reduced TNF-α-stimulated CXCL8 secretion to the same level regardless of whether the
ROCK inhibitor was administered by itself or concomitantly with the PKC inhibitor or
with the MEK inhibitor (Figure 3.10). It should be noted that, in both cases, treatment
with the MEK or PKC inhibitor resulted in a slight, but statistically significant, decrease
in TNF-α-induced CXCL8 secretion in the absence of ROCK inhibition. However, these
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decreases were not nearly of the magnitude that would be expected if either of these
kinases played any substantial role in the ROCK-dependent secretion of CXCL8.

3.7 The effect of ROCK Inhibition on TNF-α-stimulated ERK phosphorylation in
Caco-2 cells
Having identified the MEK/ERK pathway as a regulatory component moderating
TNF-α-induced CCL2 secretion, we next sought to establish the relationship, if any,
between ROCK and ERK signaling. For this, Caco-2 cells were treated with the ROCK
inhibitor and TNF-α in the previously described manner, and the cells were lysed at
fifteen minute intervals for 45 minutes. Western blot was then used to assess the effect of
ROCK inhibition on ERK phosphorylation.

In cells incubated without the ROCK

inhibitor, TNF-α treatment resulted in a 2.3-fold increase in the levels of phosphorylated
ERK after 15 minutes, which subsided to baseline levels by 30 minutes (Figure 3.11). In
contrast, when ROCK was inhibited, ERK phosphorylation at 15 minutes was suppressed
to baseline levels. This suggests that ROCK is an important component of the TNF-α
signaling cascade leading to ERK activation in Caco-2 cells. However, the data also
showed that ERK phosphorylation was similarly suppressed in the ROCK inhibitor
treatment group in the absence of TNF-α at time zero (p < 0.05). Furthermore, TNF-α
stimulation of the ROCK inhibitor-treated cells still resulted in a significant increase in
the phosphorylation of ERK at 15 minutes compared to the zero-minute levels (p < 0.05).
Thus, ROCK inhibition may not have affected the ability of TNF-α to stimulate ERK
phosphorylation but did limit the scale of the effect such that peak levels of
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phosphorylated ERK in ROCK inhibitor-treated cells only reached baseline levels of cells
treated without inhibitor.
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Figure 3.1: Inhibiting ROCK in TNF-α-treated Caco-2 cells results in a suppression
of CXCL8 secretion but an enhancement of CCL2 and CCL20 secretion. FN-coated
24-well culture plates were seeded with Caco-2 cells in FBS-DMEM and incubated at
37°C for 1 h to allow the cells to attach. The medium was then aspirated and replaced
with ITS-DMEM with or without 40 µM ROCK inhibitor (RI). The cells were returned
to the incubator for 2 h and then treated with 10 ng/mL TNF-α. After an additional 24 h
period of incubation, culture supernatants were collected and analyzed by ELISA for the
indicated chemokines, and the number of cells in each well was determined. The
resulting chemokine concentrations were then normalized to cells/well. Shown here are
the averages ± 1 SEM of three replicates. (Ctl, untreated controls; ** p < 0.01,
*** p < 0.0001)
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Figure 3.2: The suppression of CXCL8 secretion and the enhancement of CCL2 and
CCL20 secretion are also seen when ROCK is inhibited in IL-1β-treated Caco-2
cells. Cells were plated and pre-treated with ROCK inhibitor as described in Figure 3.1.
The cells were then incubated with or without 1 ng/mL IL-1β for 24 h. The
concentrations of the indicated chemokines in the resultant culture supernatants were then
determined by ELISA and normalized to the number of cells in each well. Bars represent
the means ± 1 SEM of three independent experiments. Note: IL-1β treatments were run
in the same experiments as the TNF-α treatments described in Figure 3.1. Thus, both
treatments are compared to common controls, and the same control data (Ctl and RI) are
displayed in both Figures 3.1 and 3.2. (Ctl, untreated controls; * p < 0.05,
** p < 0.001, ** p < 0.0001)
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Figure 3.3: Inhibition of ROCK in TNF-α-stimulated Caco-2 cells results in a
significant reduction in CXCL8 mRNA expression and a significant increase in
CCL2 mRNA expression. Caco-2 cells were plated and pre-treated with 40 µM ROCK
inhibitor as described in the Materials and Methods. The cells were then treated with
10 ng/mL TNF-α, incubated for 6 h, and lysed. Total RNA was extracted from each
sample and analyzed by real-time RT-PCR for CXCL8 (A) and CCL2 (B) transcript
levels using GAPDH as the reference gene. The graphs display the means (± 1 SEM) of
relative mRNA levels normalized to unstimulated controls. (n = 3; *** p < 0.002).
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Figure 3.4: Inhibition of ROCK in IL-1β-stimulated Caco-2 cells results in a
significant increase in CCL2 mRNA expression. Caco-2 cells were plated and
incubated in the presence of the ROCK inhibitor as previously described. IL-1β
(1 ng/mL) or plain medium was added to the appropriate wells, and the cells were
incubated for another 6 h. Total RNA extracts were then prepared and analyzed via realtime RT-PCR to quantify the relative expression of CCL2 mRNA. The resulting means
± 1 SEM of three independent experiments are presented here. (** p < 0.0005).
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Figure 3.5: The effect of varying the dose of ROCK inhibitor on TNF-α-induced
CCL2 mRNA expression in Caco-2 cells. Caco-2 cells suspended in FBS-DMEM were
added to the wells of FN-coated culture plates and incubated for 1 hr, allowing the cells
to attach. The medium was then removed and replaced with ITS-DMEM containing
ROCK inhibitor at the indicated concentrations. After 2 h in the presence of the ROCK
inhibitor, the cells were treated with TNF-α (10 ng/mL) and incubated for an additional
6 h. The cells were then lysed, and relative CCL2 mRNA levels were subsequently
determined by real-time RT-PCR as described in the Materials and Methods. The means
± 1 SEM from 3 separate experiments are shown here. (* p < 0.01 versus cells treated
with TNF-α alone).
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Figure 3.6: The differential regulation of CCL2 and CXCL8 is not achieved through
changes in mRNA stability. To examine mRNA stability over time, Caco-2 cells were
first subjected to pre-treatment with 40 µM ROCK inhibitor and then treated with TNF-α
(10 ng/mL) for 6 h as described in Figure 3.3. At the end of the 6 h, Actinomycin D
(ActD) was added to the culture medium at a concentration of 10 μg/mL to halt
transcription. The cells were returned to the incubator and lysed after 0, 30, 60 or 120
min of Actinomycin D treatment. RNA was purified from the resulting lysates, and the
relative expression of CCL2 (A) and CXCL8 (B) mRNA normalized to GAPDH mRNA
was assessed with real-time RT-PCR. Average mRNA levels expressed as a percents of
the zero-time control for each treatment condition are shown in the graphs
(n = 2).
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Figure 3.7: The PI3K inhibitor, Wortmannin, has no effect on the enhancement of
TNF-α-induced CCL2 secretion that results from inhibiting ROCK. Caco-2 cells
seeded in 24-well FN-coated plates were treated with the ROCK inhibitor and
10 ng/mL TNF-α as described in Figure 3.1. However, in these trials, Wortmannin at
10 or 100 nM (or vehicle) was added to the culture medium 1 h prior to the addition of
TNF-α. The concentration of secreted CCL2 in culture supernatants collected 24 h after
the addition of TNF-α was measured using ELISA and normalized to cells/well. The
averages from three separate experiments are shown (± 1 SEM). Letters demarcate
groups of statistically similar treatment conditions with each group being significantly
different from the others (p < 0.0001).
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Figure 3.8: The effect of the Akt inhibitor, triciribine, on the enhancement of CCL2
secretion by ROCK inhibition in TNF-α-stimulated Caco-2 cells. Caco-2 cells pretreated with 40 µM ROCK inhibitor were stimulated with TNF-α for 24 h using the
method detailed in Figure 3.1 with the exception that triciribine was added at the
indicated concentrations 30 min before TNF-α addition. At the end of the TNF-α
treatment, culture supernatants were collected, and the cells in each well were counted.
ELISA was used to quantify secreted CCL2, which was then normalized to cells/well.
Shown here are the means ± 1 SEM from three independent trials. Statistically
significant differences exist between treatment conditions not sharing the same letter
label (p < 0.05).
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Figure 3.9: The effects of inhibiting PKC or ERK signaling on ROCK-mediated
suppression of TNF-α-induced CCL2 secretion. Caco-2 cells were pre-treated with
40 µM ROCK inhibitor and stimulated with 10 ng/mL TNF-α, according to the procedure
specified in Figure 3.1, except that 30 min prior to TNF-α addition, the cells were treated
with either (A) the PKC inhibitor, GF109203X, at 2.5 µM, (B) the MEK inhibitor,
PD98059, at 25 µM (or vehicle). After 24 h of TNF-α stimulation, CCL2 secretion was
evaluated by ELISA. Means ± 1 SEM of three experimental replicates are displayed
above. In each replicate, both GF109203X and PD98059 treatments were performed
alongside a single set of vehicle-only controls. The vehicle-only data are shown twice for
ease of comparison. In each graph, treatment conditions not sharing a common letter
label are significantly different (p < 0.01).
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Figure 3.10: The effect of inhibiting PKC or ERK signaling on the suppression on
CXCL8 secretion that results from inhibiting ROCK in TNF-α-stimulated
Caco-2 cells. Caco-2 cells were pre-treated with 40 µM ROCK inhibitor, treated with
either (A) the PKC inhibitor, GF109203X, at 2.5 µM or (B) the MEK inhibitor,
PD98059, at 25 µM (or vehicle), and then stimulated with TNF-α for 24 h as described in
Figure 3.9. Culture supernatants from the three independent experiments were analyzed
for CXCL8 content using ELISA, and the resulting concentrations were normalized to
cells counts. As in Figure 3.9, data for the vehicle-only controls are shown twice for ease
of comparison. In each graph, letters indicate groups of statistically similar treatment
conditions.
Differences
between
groups
are
statistically
significant
(p < 0.05 for group b vs. c, p < 0.001 for all other comparisons).
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Figure 3.11: ROCK inhibition leads to the suppression of ERK phosphorylation.
FN-coated 12-well plates were seeded with Caco-2 cells and incubated for 1 h to allow
the cells to attach. The cells were then pre-treated with 40 µM ROCK inhibitor for 2 hr
as described in the Materials and Methods, followed by TNF-α (10 ng/mL) treatment for
the indicated times. Cytoplasmic proteins were separated via SDS-PAGE and analyzed
by Western blot. Blots were probed for phosphorylated ERK1/2 and total ERK1/2.
(A) A representative blot. (B) Graph displaying the means (± 1 SEM) of the ratios of
phosphorylated ERK band densities to total ERK band densities (n = 5; * p < 0.05,
** p < 0.01, *** p < 0.001). Letter labels denote groups within the TNF-α + RI data
subset determined to be significantly different by ANOVA with Fisher’s PLSD (group a
vs. group b: p < 0.05).
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4. Discussion
Several chemokines are found at abnormally high levels in IBD and thus likely
play important, and perhaps critical, roles in the pathophysiology of IBD. IEC are
important components of mucosal immunity and are known to produce chemokines in
response to pro-inflammatory signals. Understanding how chemokines are regulated at
the mucosal surface may provide opportunities to control the recruitment of leukocytes
into affected tissues and thus to control the progression or the maintenance of the chronic
inflammation that characterizes IBD.
Previous results in our laboratory have indicated that ROCK is required for
optimal production of the neutrophil chemoattractant, CXCL8, in cytokine-stimulated
IEC [176; Chapter 2]. Results in this study show that ROCK plays yet another role in
regulating chemokines in IEC. Unlike the suppressive effect of ROCK inhibition on
CXCL8, inhibiting ROCK in Caco-2 cells treated with TNF-α or IL-1β resulted in an
enhancement of secretion and mRNA levels of CCL2 and CCL20, two C-C chemokines
that are also implicated in the pathophysiology of IBD.

Furthermore, the relative

enhancement of secretion seen with ROCK inhibition closely mirrored the enhancement
of mRNA levels. Our results also showed that this enhancement of mRNA did not occur
through a reduction in the mRNA decay rate. Therefore, it appears that ROCK activation
may suppress CCL2 and CCL20 responses in these cells by reducing mRNA levels
through the downregulation of transcription. Subsequently, our studies suggest that the
effect of ROCK signaling that controls the production of CCL2 in TNF-α-treated Caco-2
cells may be transduced through the ERK pathway, as inhibiting MEK had the same
enhancement effect on TNF-α-induced CCL2 secretion as did inhibiting ROCK, while
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inhibiting ROCK resulted in a significant decrease in TNF-α-induced ERK
phosphorylation. Therefore, a working hypothesis would be that TNF-α activates ERK
through the action of ROCK and then ERK subsequently suppresses the TNF-α-induced
mRNA expression and secretion of CCL2. However, the mechanism by which ERK
affects CCL2 production is still unclear.
To our knowledge, this is the first report of a suppressive regulatory role for
ROCK in the production of pro-inflammatory cytokines. As recent research has begun to
focus more attention on ROCK and, in particular, its role in chemokine production, there
have been reports of ROCK-dependent CCL2 regulation in LPA-treated HUVECs [209],
angiotensin-II-treated human hepatic stellate cells [259], TNF-α-treated mouse mesangial
cells [260], and IL-1β-treated rat IEC-6 cells [176]. Less is known about the role of
ROCK in CCL20 production, although one study found that CCL20 mRNA expression
was dependent on ROCK activity in human articular chondrocytes exposed to repetitive
compression [261]. In all these cases, ROCK was shown to be a required, positive
regulator of CCL2 or CCL20 production. The suppression of CCL2 and CCL20 by
ROCK in IEC is a novel finding and may be exclusive to IEC, or perhaps to all barrier
cell types, possibly providing a mechanism for finer control of immunological responses
in areas with a high degree of contact with a multitude of foreign antigens and organisms.
That inhibiting ROCK resulted in an enhancement of CCL2 and CCL20 responses
was a surprising result, which ran contrary to our initial hypothesis. After this effect was
confirmed at the mRNA level, strong evidence against the possibility that the
enhancement was due to an off-target effect of the Y-27632 inhibitor was obtained from
dose-response experiments. These results, taken together, indicate that it is likely that
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ROCK is an essential component of a negative regulatory mechanism that suppresses
CCL2 and CCL20 production. Furthermore, the fact that ROCK inhibition enhanced
CCL2 and CCL20 responses while simultaneously suppressing the CXCL8 response
suggests that ROCK mediates at least two independent downstream regulatory pathways
governing chemokine responses in IEC. However, the Y-27632 ROCK inhibitor can
affect other kinases, and to show absolutely that the effect on CCL2 and CCL20 secretion
was due to ROCK, RNA interference using small interfering RNAs (siRNAs) to
knockdown ROCK levels must be done.
To characterize the role of ROCK in IEC chemokine responses, we next focused
our investigations on the mechanisms underlying the ROCK-mediated regulation of
CXCL8 and CCL2. Data from this investigation suggest that the mechanism by which
ROCK moderates the secretion of CCL2 in IEC is through the down-regulation of signal
transduction and transcription.

When ROCK was inhibited in Caco-2 cells, CCL2

mRNA levels increased 1.7-fold in TNF-α-treated cells (Figure 3.3B) and 1.8-fold in
IL-1β-treated cells (Figure 3.4). These increases corresponded to respective 2-fold and
1.5-fold increases in CCL2 secretion. While the comparison of the CCL2 transcript
levels at 6 hours to the levels of secreted CCL2 protein accumulated over 24 hours does
not definitively rule out translational regulation, the fact that ROCK inhibition resulted in
equivalent increases in both mRNA levels and secretion levels makes it unlikely that the
ROCK-dependent attenuation of CCL2 was occurring through the translational mode of
control. Any suppression of CCL2 translation by ROCK would have amplified the
suppression of mRNA expression resulting in levels of CCL2 secretion significantly
lower than those observed.
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The contention that ROCK-mediated suppression of CCL2 in IEC most likely
occurs only through transcriptional regulation, but not post-transcriptional regulation, is
further supported by results from our experiments examining mRNA stability. Despite
the fact that the modulation of mRNA stability is one of the major ways that chemokines
are regulated [242], in our experiments, the inhibition of ROCK in TNF-α-treated Caco-2
cells did not lead to increased stability of CCL2 mRNA nor to decreased stability of
CXCL8, as would be expected if ROCK were exerting an effect in this way. It should be
noted that blocking ROCK did produce a decrease in the stability of CCL2 mRNA at the
2-hour time point. However, this runs counter to the increase in CCL2 transcript levels
seen with ROCK inhibition, since decreased stability would result in reduced mRNA
levels. Thus, this difference is probably an artifact of the small sample size (n = 2).
While at least one study has implicated ROCK in the modulation of mRNA decay [262],
our results indicate that this mode of regulation is not utilized in the ROCK-dependent
mechanisms regulating CXCL8 and CCL2 production in TNF-α-stimulated IEC.
Furthermore, in previous experiments, the inhibition of ROCK in Caco-2 cells was shown
to have no effect on TNF-α-induced activation of p38 MAPK (Figure 2-3), a pathway
known to play a major role in regulating both mRNA stability and translational control
[205, 206, 263]. Although it has been shown that ROCK has the ability to affect mRNA
stability in at least one other system [262], our investigations found no evidence of
ROCK-mediated post-transcriptional regulation in IEC, and therefore, our data support a
transcription-level-only model of ROCK-mediated regulation of TNF-α-stimulated
CXCL8, CCL2, and CCL20 production.
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Our previous experiments showed that the TNF-induced activation of the NF-κB
and p38 MAPK pathways in Caco-2 cells occurs independently of ROCK under our
conditions, while JNK was found to be a downstream effector of ROCK in TNF-αstimulated cells (Chapter 2).

Since JNK is a well-known mediator of CXCL8

transcription [194, 197-200], it seemed unlikely that this kinase would also be involved in
the suppression of CCL2, and thus, we continued our search for other TNF-α-activated
and ROCK-mediated pathways. While several reports have linked the PI3K/Akt pathway
to the regulation of CCL2 [153, 154, 256, 264, 265], in our experiments, neither
inhibiting PI3K with Wortmannin nor inhibiting Akt with triciribine had any effect on the
ROCK-mediated enhancement of TNF-α-induced CCL2 secretion. This result, however,
was not surprising, since CCL2 production is not always regulated via PI3K/Akt [266,
267]. Still, it is possible that Akt may play a minor role in regulating TNF-α-stimulated
CCL2 secretion independently of ROCK, as treatment with the highest dose of triciribine
(10 µM) did produce a modest, overall decrease in TNF-α-induced CCL2 levels
regardless of whether ROCK was inhibited. Similarly, the PKC inhibitor, GF109203X,
had little or no effect on the ROCK-dependent CCL2 attenuation in TNF-α-stimulated
Caco-2 cells.
The first evidence identifying one of the signaling molecules that partner with
ROCK in suppressing CCL2 came from treating TNF-α-treated Caco-2 cells with the
PD98059 inhibitor.

This inhibitor is highly specific for MEK1/2, the only known

activators of ERK1/2 [168]. In our experiments, the blockade of MEK, and hence ERK
signaling, resulted in enhanced TNF-α-induced CCL2 secretion. A comparable effect
was also demonstrated by Pastore et al. [268] who found that TNF-α-induced expression
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of CCL2, CCL5, and CXCL10 was likewise enhanced by inhibiting ERK signaling in
keratinocytes. In addition, over-expression of ERK in HUVECS has been found to
suppress VCAM-1 and ICAM-1 expression induced with either TNF-α or IL-1β [269].
In our experiments, the enhancement of CCL2 seen with the inhibition of MEK was
nearly identical to the enhancement seen with the inhibition of ROCK as well as to the
enhancement seen with the co-inhibition of ROCK and MEK together. That inhibiting
ROCK, inhibiting MEK, or inhibiting both in tandem produced such similar regulatory
outcomes suggests that ROCK and ERK may be required factors in the transduction of
the signal that directs the attenuation of TNF-α-induced CCL2 secretion. Moreover,
inhibiting MEK had little or no effect on TNF-α-stimulated CXCL8 responses, which
indicates that the MEK/ERK pathway is part of a CCL2-focused signaling branch that
diverges from the pathway regulating CXCL8.
This appears to be a unique finding in epithelial cells as other studies of the
regulatory effects of ERK on both CCL2 and CXCL8 expression in different epithelial
cell lines and primary cultures have found these chemokines to both be under the control
of ERK. For example, ERK signaling has been found to suppress TNF-α-induced CCL2
secretion in keratinocytes, much like we observed in Caco-2 cells, while ERK was also
found to simultaneously enhance CXCL8 secretion in those cells [268]. Thus, while the
overall pattern of differential CCL2 and CXCL8 regulation is parallel to that in Caco-2
cells, the divergence of regulatory signals in keratinocytes occurs downstream of ERK,
since the activation of ERK was required for both effects, a finding that is in
contradiction with our observations in Caco-2 cells. More commonly, both CCL2 and
CXCL8 have been found to be positively regulated by ERK. Experiments with human
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peripheral blood mononuclear cells, corneal fibroblasts, renal proximal tubule cells,
retinal pigment epithelial cells, and several other cell types have all shown that the full
and concurrent induction of CCL2 and CXCL8 is dependent on ERK activation in a
variety of pro-inflammatory conditions [255, 256, 270, 271]. It is unclear why CCL2, but
not CXCL8, would be regulated by ERK in our cells when the regulation of both
chemokines by ERK appears to be the norm for most other cell types. Perhaps reduced
CCL2 and CCL20 levels confer an advantage in maintaining or restoring the intestinal
barrier in pro-inflammatory conditions that favor the activation of ERK, or perhaps
regulating CXCL8 independently of ERK allows IEC more freedom to modulate the
amount of CXCL8 secreted and thus provides a wider array of possible responses to the
many different types of antigens and stimuli at the intestinal border.
Having found the link between ROCK and ERK, we next clarified their
relationship by examining the effect of inhibiting ROCK on TNF-α-induced ERK
phosphorylation. These experiments identified ROCK as the upstream mediator of ERK
activation in our model, which is in accord with many other examples of ROCKdependent ERK signaling that have been observed in a wide range of cell types and
settings. For instance, ROCK inhibition has been found to suppress the TNF-α-triggered
activation of ERK in human lung microvascular endothelial cells [207]. Similarly, in the
Caco-2 BBe sub-line, the impairment of ROCK signaling by chemical inhibition or by
siRNA-silencing was shown to prevent the activation of ERK that resulted from
repetitive substratum deformation [272]. While considerably less frequent, there are also
some reports of alternative relationships between ROCK and ERK. Results from two
such reports show that in bovine pulmonary artery smooth muscle cells treated with
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serotonin and in rat vascular smooth muscle cells treated with platelet-derived growth
factor, ROCK does not take part in the induction of ERK activity but instead plays an
essential role in the transmittance of the ERK signal by mediating the translocation of
activated ERK to the nucleus [273, 274]. Conversely, data from other studies have
suggested that in some cases, ERK may act as the upstream regulator of ROCK [152,
275]. It is not entirely clear why such variation in ROCK-ERK interactions would exist,
but it could help explain the diversity in the ways that different cell types can respond to
the same stimulus.
Figure 3.12 summarizes a proposed scheme of TNF-α and ROCK signaling in our
system.

TNF-α induces the ROCK-dependent activation of JNK and the ROCK-

independent activation of NF-κB, both of which lead to increased CXCL8 expression.
Simultaneously, TNF-α stimulation activates ERK, which requires ROCK for maximal
activation and leads to suppressed CCL2 and CCL20 production. Because TNF-α can
activate ERK even when ROCK is inhibited, it appears likely that ROCK is potentiating
ERK activation and not mediating the TNF-α signal to ERK.
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Figure 3.12: Possible modes of TNF-α and ROCK signaling involved in the
differential regulation of CXCL8, CCL2, and CCL20 in Caco-2 cells attached to a
FN substratum.

112

What is more striking is that our results indicate that ROCK exerts it effect on
ERK phosphorylation independently of TNF-α signaling.

The blockade of ROCK

suppressed the phosphorylation of ERK regardless of whether or not the cells were
treated with TNF-α (See Figure 3.11), and ROCK inhibition had no effect on the ability
of TNF-α to elicit ERK phosphorylation, nor did it affect the relative increase in or
kinetics of TNF-α-induced ERK phosphorylation. So, while these results suggest that
ROCK does not directly transduce the TNF-α-to-ERK signal in IEC, it does appear that
ROCK activity potentiates ERK signaling and does so in a manner consistent with
crosstalk between two independently activated pathways.
The control of simultaneously induced chemokines via separate regulatory
mechanisms has been reported for a variety of chemokines in several different cell types.
In HT-29 CL19A human colorectal cancer cells, IL-17 treatment has been found to
abolish TNF-α-induced CCL5, CXCL10, and CXCL11 mRNA expression while inducing
significant increases in CXCL1, CXCL8, and CCL20 mRNA levels [276]. In another
study, the blockade of EGF receptor kinase activity in cells stimulated with TNF-α
resulted in the concurrent enhancement of CCL2, CCL5, and CXCL10 responses and
suppression of CXCL8 responses [277]. Interestingly, the differential effects of EGF
receptor inhibition on CCL2 and CXCL8 observed in keratinocytes parallel the
differential effects of ROCK inhibition we found in Caco-2 cells, while in the previously
mentioned study, both CCL20 and CXCL8 mRNA levels in TNF-α-stimulated HT-29
CL19A cells were found to be up-regulated together, in contrast to our results.
The number and variety of intracellular signaling mechanisms that have been
discovered thus far to be involved in modulating chemokine production is evidence of
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complex regulatory systems, most likely specific to cell type, that are capable of making
both subtle and extreme changes in the array of chemokines released in response to wide
ranges of ever-changing conditions. Such systems may be a way for cells to call in
particular sets of leukocytes in order to form specialized immunological networks with
distinct functions, such as precise responses to specific types of pathogens, the resolution
of inflammation, or the maintenance of tolerance. We have shown here that ROCK can
differentially affect the production of CCL2, CCL20, and CXCL8 in IEC treated with
TNF-α or IL-1β. CXCL8 is a chemokine that attracts primarily neutrophils [99, 108],
while CCL2 attracts mainly macrophage and monocytes [99, 101, 108], and CCL20
attracts dendritic cells and specific subsets of T lymphocytes, including TH17 cells [100,
101, 113]. Since each of these chemokines attracts a distinct subset of leukocytes, these
results suggest that ROCK may be an important component of mechanisms governing the
profile of leukocytes mobilized during intestinal inflammation, particularly in conditions
that favor the activation of ROCK.
As previously described in Chapter 2, we proposed that the in vitro model used in
these experiments was applicable to IEC at the edges of intestinal ulcerations that occur
in IBD. During our experiments, the Caco-2 cells attached, spread, and began migrating
toward one another, remaining subconfluent the entire time. These cellular activities
require the formation and turnover of focal adhesions and stress fibers, processes that are
known to involve both ROCK and integrins [172, 238, 278]. Integrin signaling has been
shown to activate ROCK, to activate ERK, and also to potentiate ERK signaling via
ROCK [238, 239, 279, 280].

Therefore, it seems probable that, under the given

conditions, the degree of ERK activation stimulated by TNF-α in Caco-2 cells may be a
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result of the integration of independent signals from both TNF-α- and integrin-associated
pathways. However, our data do not give a clear indication of whether the ROCKmediated signal and the TNF-α signal work additively to produce the observed activation
of ERK or whether the ROCK-mediated signal is amplifying ERK signaling in general.
Still, the fact that inhibiting ROCK in untreated controls did not completely abrogate
ERK phosphorylation seems to favor the latter explanation.
The idea that our experiments tested cells while they were sub-confluent and
moving, much like cells at the edge of wounds, in which IEC are in flux as they attempt
to migrate and cover the denuded surface, provides a physiological scenario where
ROCK is activated. Coupling chemokine secretion to ROCK activation under these
conditions may allow the intestinal epithelium to set up gradients of different chemokines
that could affect the spatial distribution of leukocytes in the wound area. For example,
our results suggest that ROCK activity is required for optimal CXCL8 secretion in IEC,
and therefore, it seems likely that the greatest production of CXCL8 would occur at the
wound edge where ROCK activity would be the highest and where neutrophils would be
most needed to defend against the influx of microorganisms.
Also, in this model, production for CCL2 and CCL20, which we showed to be
suppressed by ROCK activity, would be maximized some distance from the wound edge
where IEC would not be actively participating in wound closure, yet would be close
enough to the wound edge such that there still would be relatively high concentrations of
antigens and pro-inflammatory cytokines.

In addition to attracting monocytes and

macrophages, CCL2 has been identified as a chemoattractant for B cells, activated
T cells, and naïve dendritic cells. A gradient of CCL2 that draws these cells near, but not
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into, the wound could be advantageous for many reasons. The environment in the wound
would be inhospitable due to the cytotoxic activities of neutrophils. Thus, such a CCL2
gradient would allow B cells, T cells, and dendritic cells to activate the adaptive immune
response in relative safety and without hindering the neutrophil response, and
macrophages would be near enough to the wound to act as phagocytes while still
performing their roles as regulators of inflammation and interacting with lymphocytes as
antigen-presenting cells. In addition, CCL20 has also been found to attract TH17 cells,
which are considered to be important players in IBD [60, 61, 64]. A gradient of CCL20
centered away from the wound edge may then be important in positioning TH17 cells
around ulcerations and may play an indirect role in maintaining the chronic inflammation
of IBD.
Because ROCK is involved in the differential regulation of these chemokines and
thus, would be a necessary component for setting up the differential spatial arrangement
of chemokine gradients proposed here, the results of this study open up the possibility of
targeting ROCK or its downstream effectors in treatments designed to alleviate intestinal
inflammation by exerting precise control over the recruitment of different types of
leukocytes. The development of such treatments, however, would first require further
characterization of the ROCK-dependent regulatory mechanisms involved and a
comprehensive survey of chemokine production in IEC to determine the extent of ROCK
involvement.
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Chapter 4
Conclusions
The root cause of IBD is still unknown, but it now seems likely that it involves a
combination of a number of factors, resulting in a loss of tolerance and an abnormal
response to commensal intestinal organisms. Among the potential causes that have been
linked to IBD are genetic traits at over 70 loci, environmental factors, and changes in gut
microflora.

The hallmark of IBD pathophysiology is uncontrolled and prolonged

inflammation that leads to tissue damage and other serious consequences.

As

inflammation progresses, neutrophils infiltrate the crypt regions and surrounding tissues
and begin secreting several damaging substances, including oxidative species [281, 282].
This leads to the loss of the intestinal epithelium in inflamed areas and to the degradation
of the lamina propria extracellular matrix, creating ulcerations. In CD, if ulcers persist,
they can develop into perforations of the intestinal wall and into fistulas. The infiltration
of leukocytes and subsequent tissue damage is accompanied by abnormal overproduction
of several pro-inflammatory cytokines, for instance IL-1β, TNF-α, IL-6, CXCL8, CCL2,
and CCL20, and dysregulation of anti-inflammatory mediators, such as IL-10 and
IL-1Ra. Despite being the focus of much research, there is still much that is unknown
about this aberrant production of cytokines. Thus, understanding how inflammatory
mediators are regulated may lead to better understanding of the etiology of IBD, which,
in turn, may lead to better treatments or even a cure.
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One pro-inflammatory cytokine that is of particular importance in IBD is TNF-α.
Not only is TNF-α found at elevated levels in the serum, stool, and tissues of IBD
patients, but it is also a major and central mediator of inflammation in general. One of
the main functions of TNF-α is inducing of the expression of several additional
downstream cytokines, including the chemokines, CXCL8, CCL2, and CCL20. Due to
its central role in inflammation, TNF-α has become the main target of the current biologic
therapies. However, despite their advanced nature, these therapies have shortcomings.
They are only effective for about 40 - 60% of patients, and there is an increased risk for
serious infections.

Further research into the role of TNF-α in IBD may allow

improvement of these therapies or more likely, may lead to new therapies, which may be
more effective and have fewer side effects and risks.
Previous work in our laboratory has shown that ROCK plays a role in chemokine
responses in IEC stimulated by IL-1β, another cytokine found at elevated levels in IBD
[176]. In those studies, inhibiting ROCK led to significantly reduced levels of IL-1βinduced CXCL8 secretion and mRNA expression in Caco-2 cells. Inhibiting ROCK had
the same effect on CCL2 secretion and mRNA expression in IL-1β-treated IEC-6 rat
intestinal cells. In addition, ROCK inhibition resulted in significantly reduced IL-1βinduced activation of JNK, while having no effect on IL-1β-stimulated NF-κB activation.
These results led us to ask whether ROCK plays a similar role in TNF-α signaling and
chemokine responses in IEC. In this study, we have demonstrated that inhibiting ROCK
resulted in a significantly decreased CXCL8 secretion and mRNA expression in Caco-2
cells. Further investigation showed that, similar to the previous results with IL-1β,
ROCK inhibition suppressed p54 JNK activation. Also similar to the IL-1β results,
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TNF-α-stimulated signaling to NF-κB activation was unaffected by ROCK inhibition as
shown by unaltered IκBα phosphorylation and degradation. These results indicate that
ROCK may be an important mediator of CXCL8 responses in IEC stimulated with
TNF-α or IL-1β.
It is notable that ROCK inhibition resulted in an incomplete 46% suppression of
TNF-α-induced CXCL8 secretion and a similarly incomplete 82% reduction in mRNA
levels. This is most likely linked to the fact that ROCK inhibition had no effect on
TNF-α-stimulated signaling to NF-κB activation, while having a suppressive effect on
p54 JNK signaling.

CXCL8 expression is governed by both the AP-1 and NF-κB

transcription factors. Since AP-1 is a major target of JNK, it seems probable that the
suppression of JNK resulted in the suppression of CXCL8. However, until confirmed by
experimentation, it is unclear which pathways and transcription factors are mediating the
ROCK-dependent expression of CXCL8 and which are responsible for the unsuppressed
portion of its expression. To determine this, ELISA-based assays targeting AP-1 and
NF-κB could be used to examine TNF-α-induced transcription factor activation in the
presence or absence of the ROCK inhibitor. Additionally, experiments using inhibitors
of JNK and NF-κB in combination with the ROCK inhibitor could be run to see which
conditions lead to complete suppression of CXCL8 responses in IEC treated with TNF-α.
The fact that ROCK inhibition resulted in reduced TNF-α-stimulated JNK
activation, while leaving TNF-α-induced signaling to NF-κB unaffected, may have
further implications and may be an important piece of information for future studies. In
addition to initiating the expression of many pro-inflammatory genes, NF-κB activation
in the intestinal epithelium has been shown to be necessary for intestinal homeostasis and
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for the activation of some adaptive immune responses [1]. Thus, any potential treatment
that blocks NF-κB activity in IEC may be ineffective or have severe side effects.
However, we have demonstrated here that the ROCK inhibitor blocks only JNK
signaling. This points to a mechanism by which the production of pro-inflammatory
mediators like CXCL8 could be significantly reduced, while leaving NF-κB signaling
intact to maintain homeostasis. This makes ROCK a potentially attractive subject for
pharmaceutical research. While the Y-27632 inhibitor is not approved for human use,
two ROCK inhibitors, fasudil [283, 284] and ripasudil [285], have been approved in
Japan for the treatment of cerebral vasospasm and glaucoma, respectively, and more
inhibitors are in clinical trials in the United States for conditions other than IBD. The
work of identifying ROCK inhibitors that are safe for human use has already been done.
Therefore, further research into ROCK in intestinal contexts and subsequent clinical trials
are important if we are to take advantage of this novel therapeutic target.
In this study, we have also shown a role for ROCK in CCL2 and CCL20
production in IEC. In these cases, we found that inhibiting ROCK significantly enhanced
CCL2 and CCL20 secretion in TNF-α-treated Caco-2 cells, signifying that the activation
of ROCK may suppress CCL2 and CCL20 responses in these cells. This was in direct
contradiction to what we found for CXCL8 secretion and to a previous result in our lab
that showed that CCL2 production was significantly reduced by ROCK inhibition in
IL-1β-treated IEC-6 cells [176]. IEC-6 cells, however, are derived from rat intestine,
while Caco-2 cells are human colonic cells, and the rat immune system is sufficiently
different from that of humans as to possibly explain the discrepancy. For instance, the rat
immune system lacks a CXCL8 homolog [286]. We also showed that TNF-α-dependent
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CCL2 mRNA expression could be enhanced with ROCK inhibition and that this
enhancement was not due to increased mRNA stability. Inhibiting ROCK led to a similar
pattern of enhancement of CCL2 and CCL20 secretion and of CCL2 mRNA expression
in IL-1β-treated Caco-2 cells as well. In addition, we found that the ROCK-dependent
suppression of TNF-α-induced CCL2 secretion was mediated by ERK. Furthermore,
ROCK inhibition suppressed both TNF-α-stimulated ERK phosphorylation and baseline
levels of ERK phosphorylation independently of TNF-α. However, even with ROCK
inhibition, TNF-α was still able to activate ERK but at considerably lower levels
(Figure 3.11).
In order for baseline levels of ERK phosphorylation to be suppressed by ROCK
inhibition, the effect of ROCK on ERK signaling must originate, at least partially, from a
source other than TNF-α. Since ROCK is involved in stress fiber formation and focal
adhesion turnover, both of which also involve integrins, we propose that the baseline
portion of ROCK activity that was observed in our cells is possibly due to integrin
signaling (Figure 3.12). It is known that integrin signaling can activate ERK [238, 279],
and one study found that Rho mediated integrin-dependent ERK signaling in NIH 3T3
cells plated on FN [239], suggesting a possible role for ROCK in this process. To
determine whether integrin signaling is involved in ERK signaling in Caco-2 cells and
what role integrins may play in TNF-α signaling, antibodies that neutralize specific
integrins could be used in experiments examining baseline and TNF-α-induced ERK
activation. The α5β1 integrin is a particularly good candidate as it has previously been
shown to mediate FN-induced activation of ERK in Caco-2 [287] and rat IEC cell lines
[288].
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Another important result from this study was the differential regulation by ROCK
of CXCL8 versus CCL2 and CCL20. Inhibiting ROCK decreased the CXCL8 response
while enhancing CCL2 and CCL20 responses, indicating that ROCK activity was
required for optimal CXCL8 production while suppressing CCL2 and CCL20 production.
This increase in CCL2 and CCL20 with ROCK inhibition may seem to suggest that
ROCK inhibitors may not be ideal for treatment as the increase in these chemokines may
still draw inflammatory cells into intestinal tissues. However, macrophages, the main
targets of CCL2, are also known to play an important role in healing processes as well.
Macrophages can produce anti-inflammatory cytokines, such as IL-10 and TGF-β, that
direct a transition to healing conditions by 1) repressing the production of proinflammatory molecules in both an autocrine and paracrine manner and 2) inducing the
expression of anti-inflammatory and healing-related substances, including growth factors,
angiogenic factors, and protease inhibitors (which prevent further tissue damage) [54].
Furthermore, the drop in CXCL8 seen with ROCK inhibition would reduce inflammatory
conditions by reducing the number neutrophils in the affected tissues, and thus could
potentially tip the balance toward anti-inflammatory conditions. Still, more must be
known to determine whether or not ROCK inhibition may be an effective therapeutic
strategy. For instance, the questions of what other chemokines are regulated by ROCK in
IEC and whether that regulation differs between CXC and CC chemokines (or some other
delineation) still remain.

To investigate these questions, one of the commercially

available ELISA-based chemokine arrays could be employed in experiments with IEC
treated with TNF-α and ROCK inhibitor.
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In this work, we have proposed that our experimental system best models IEC at
the edge of intestinal ulceration. Not only did the Caco-2 cells attach to the substratum,
spread, and begin migrating toward one another during the course of our experiments, but
the cells also remained subconfluent the entire time. We propose that these conditions
are much like the edge of ulcerations where the IEC are also subconfluent and also spread
and migrate in an attempt to cover the denuded lamina propria. Attachment, spreading
and migration are all processes that are known to involve integrins and ROCK. Thus,
this model, taken together with our results, suggests that IEC may produce different
spatial arrangements of chemokine gradients, as ROCK would be considerably more
active at the wound edge. Specifically, since we found that ROCK activity was required
for optimal CXCL8 secretion under inflammatory conditions (i.e. in the presence of
IL-1β and/or TNF-α), peak CXCL8 production would be expected at the edge of an
ulceration (Figure 4.1). In contrast, we would expect TNF-α- and IL-1β-induced CCL2
and CCL20 production to be suppressed at the wound edge since our experiments showed
that ROCK activity reduced CCL2 and CCL20 secretion. Unchecked, these gradients
would draw neutrophils to the center of the wound where they could 1) mount a defense
against invading microbes and 2) cause additional and prolonged tissue damage. These
gradients would also draw macrophages, T cells, and other leukocytes to an area some
distance from periphery of the ulceration where they could direct the progression of the
inflammatory response and mount additional defenses. In this model, disrupting these
gradients with a ROCK inhibitor would lead to a drop in CXCL8 and thus a drop in
neutrophils at the wound center. In this scenario, a ROCK inhibitor would also increase
CCL2 production at the wound edge drawing macrophages closer to where healing
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processes would be needed. While this is merely hypothetical at this point, our data plus
the work of Segain et al. [123] suggest that ROCK inhibitors could be important antiinflammatory agents that could help IBD patients achieve remission.
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Figure 4.1: Proposed pattern of chemokine gradients produced by IEC at the edge
of intestinal ulcerations. A) Due to increased ROCK activity in IEC at the wound edge,
CXCL8 production (red) would be highest there and decrease with distance from the
wound center. B) CCL2 and CCL20 production (blue) would be suppressed at the wound
edge. Thus, the peak of secretion of both these chemokines would be some distance from
the wound edge. A representation is shown here for the expected distribution of
C) neutrophils and D) macrophages and lymphocytes based on the proposed gradients.
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While, in this work, we have identified ROCK as an important regulator of
chemokine production in IEC and a mediator of TNF-α signaling, many questions still
remain about the role of ROCK in IEC inflammatory responses. As previously noted,
aside from CXCL8, CCL2, and CCL20, a full inventory of chemokines that are under the
control of ROCK has yet to be taken. In addition, much is unknown about the exact
position that ROCK occupies in the TNF-α signaling cascade. For instance, the exact
Rho protein that activates ROCK has not been identified, nor have any regulators
upstream of that Rho, such as guanine nucleotide exchange factors or GTPase-activating
proteins. It is also unclear how ROCK fits into JNK signaling. The MAP3K for JNK in
TNF-α-stimulated IEC is still unknown, and it is uncertain whether ROCK directly
activates a MAP3K or if it regulates JNK signaling by phosphorylating a scaffold protein.
Another question is how ROCK potentiates ERK signaling and whether or not integrins
are involved. Elucidating these pathways and the full extent of the effect of ROCK in
IEC chemokine responses may provide important clues that could either confirm ROCK
as a good target for therapeutic intervention or could identify additional therapeutic
targets.
In conclusion, we have shown here that ROCK plays a critical role in TNF-αinduced chemokine responses in IEC.

Furthermore, we showed that there was a

differential effect of ROCK between CXCL8 and both CCL2 and CCL20, although the
significance of this is as yet unclear. Still, the ability of ROCK to regulate these proinflammatory makes ROCK a good potential candidate for continued pharmaceutical
research. In addition, ROCK was also found to regulate JNK, but not NF-κB. This
suggests that a ROCK inhibitor drug could reduce IEC inflammatory responses by
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suppressing JNK, while allowing NF-κB-dependent IEC homeostasis to go unaffected.
Taken together, along with the work of the Segain group [123], our results suggest that
ROCK inhibition could be an effective strategy for the induction of remission in IBD.
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